WO2022161493A1 - 氮杂麦角林类衍生物及其制备方法和应用 - Google Patents

氮杂麦角林类衍生物及其制备方法和应用 Download PDF

Info

Publication number
WO2022161493A1
WO2022161493A1 PCT/CN2022/075094 CN2022075094W WO2022161493A1 WO 2022161493 A1 WO2022161493 A1 WO 2022161493A1 CN 2022075094 W CN2022075094 W CN 2022075094W WO 2022161493 A1 WO2022161493 A1 WO 2022161493A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
formula
membered heteroaryl
compound
group
Prior art date
Application number
PCT/CN2022/075094
Other languages
English (en)
French (fr)
Inventor
程建军
汪胜
王欢
樊鲁玉
陈章成
余竞
祁建忠
聂芬
Original Assignee
上海科技大学
中国科学院分子细胞科学卓越创新中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海科技大学, 中国科学院分子细胞科学卓越创新中心 filed Critical 上海科技大学
Priority to JP2023546362A priority Critical patent/JP2024504499A/ja
Priority to US18/274,889 priority patent/US20240124456A1/en
Priority to EP22745364.4A priority patent/EP4286384A1/en
Publication of WO2022161493A1 publication Critical patent/WO2022161493A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to an aza-ergoline derivative and a preparation method and application thereof.
  • the dopaminergic signaling pathway is related to human movement, behavior, emotion, memory and other physiological functions, and has been one of the focuses of neurobiological research in recent decades.
  • the dysfunction of dopaminergic signaling pathway is considered to be the pathogenesis of various diseases such as Parkinson's disease and schizophrenia.
  • the dopaminergic signaling pathway consists of the neurotransmitter dopamine, dopamine receptors, and downstream signaling molecules associated with dopamine receptors.
  • Dopamine receptors belong to the G protein-coupled receptor (GPCR) superfamily and are one of the most important central nervous system (CNS) drug targets.
  • GPCR G protein-coupled receptor
  • D1-5 dopamine receptors
  • D1 and D5 are D1 receptors, which are mainly coupled with G s protein and increase intracellular cAMP levels after activation
  • D2, D3, and D4 are D2 receptors. It is mainly coupled to the G i protein and reduces intracellular cAMP levels upon activation.
  • Different dopamine receptors have different expression levels and distributions in the central nervous system and exert different physiological functions (Martel and McArthur, Front Pharmacol 2020, 11:1003).
  • the dual action of D2 receptors and 5-HT 2A receptors is a common feature of these drugs.
  • Krogsgaard-Larsen et al. reported a compound A with an azaergoline skeleton. Its derivative A1 has the binding activity of 5-HT 6 receptor, the derivative A2 has the agonistic activity of dopamine D2 receptor, and A3 has dopamine D2 receptor agonistic activity. Partial agonistic activity of the body (Krogsgaard-Larsen et al., J. Med. Chem. 2014, 57, 5823-5828; WO2011088836; WO2011088838). The target selectivity, animal in vivo activity and other druggability of these compounds have not been reported.
  • the technical problem to be solved by the present invention is that the existing compounds with affinity, agonistic activity or selectivity for dopamine D2 receptors are few in type. Therefore, the present invention provides an azaergoline derivative and a preparation method thereof. and application. The compounds of the present invention have good affinity, agonistic activity or selectivity for dopamine D2 receptors.
  • the present invention provides a compound shown in formula I, a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of a pharmaceutically acceptable salt thereof:
  • L is C 1-10 alkylene, C 2-10 alkenylene, C 2-10 alkynylene or -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • Q 1-1 is independently halogen or C 1-4 alkyl
  • Q 1-2 is independently C 1-4 alkyl, oxo or hydroxy
  • R 1 and R 2 are independently -NR 1-1 R 1-2 , 3-6 membered heterocycloalkyl, C 6-18 aryl, C 6-18 substituted with 1 or more R 1-3 Aryl, 5-10-membered heteroaryl or 5-10-membered heteroaryl substituted by 1 or more R 1-4 ; the heteroatoms in the 3-6-membered heterocycloalkyl are N, S Or one or more of O, and the number is 1, 2 or 3; the heteroatom in the 5-10-membered heteroaryl group is one or more of N, S or O, The number is 1, 2 or 3; the heteroatom in the 5-10-membered heteroaryl substituted by 1 or more R 1-4 is one or more of N, S or O species, the number is 1, 2 or 3;
  • R 1-1 , R 1-2 , R 1-3 and R 1-4 are independently C 1-4 alkyl
  • R is hydrogen or C 1-4 alkyl.
  • the compound shown in the formula I is the compound shown in the formula Ia, Ib or Ic:
  • the compound shown in the formula I is the compound shown in the formula Id and/or Ie, preferably the compound shown in the formula Id;
  • the carbon atom marked with "*" is a chiral carbon atom; (+) represents a dextrorotatory compound, and (-) represents a levorotatory compound.
  • L is C 1-10 alkylene, C 2-10 alkenylene or -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • R is hydrogen
  • L is C 1-10 alkylene or -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • M is -O-, -NH- or -CH 2 -;
  • L is C 1-10 alkylene or -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • M is -O-, -NH- or -CH 2 -;
  • Q 1-2 is C 1-4 alkyl or hydroxyl
  • the number of heteroatoms in the 5-10-membered heteroaryl group is one.
  • L is C 1-10 alkylene or -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • M is -O-, -NH- or -CH 2 -;
  • C 1-6 in the -C 1-6 alkylene-C 3-6 cycloalkylene- Alkylene is ethylene.
  • L is C 1-10 alkylene or -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • M is -O- or -NH-
  • R 1 is -NR 1-1 R 1-2 .
  • L is C 1-10 alkylene
  • M is -O-
  • Q is a 5-10-membered heteroaromatic substituted with one or more Q 1-2 .
  • L is -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • M is -NH-
  • R 1 is -NR 1-1 R 1-2 .
  • L is C 1-10 alkylene or C 2-10 alkenylene
  • Q is a 5-10 membered heteroaryl group, or a 5-10 membered heteroaryl group substituted with one or more Q 1-2 .
  • L is C 1-10 alkylene or C 2-10 alkenylene
  • Q is C 6-18 aryl substituted by 1 or more Q 1-1 , 5-10-membered heteroaryl, or, 5-10-membered heteroaryl substituted by 1 or more Q 1-2 ;
  • Q 1-1 is halogen
  • L is -C 1-6 alkylene-C 3-6 cycloalkylene-;
  • R 1 and R 2 are independently -NR 1-1 R 1-2 , 3-6 membered heterocycloalkyl, C 6-18 aryl or 5-10 membered heteroaryl.
  • Y is hydrogen, hydroxyl or oxygen
  • L is C 1-10 alkylene
  • Q is C 6-18 aryl substituted by 1 or more Q 1-1 , or, 5-10-membered heteroaryl substituted by 1 or more Q 1-2 ;
  • Q 1-1 is halogen
  • Q 1-2 is independently C 1-4 alkyl or oxo.
  • L is C 1-10 alkylene
  • Q is C 6-18 aryl substituted by 1 or more Q 1-1 ;
  • Q 1-1 is halogen
  • R is hydrogen
  • L is C 1-10 alkylene
  • Q is C 6-18 aryl substituted by 1 or more Q 1-1 ;
  • Q 1-1 is halogen
  • R is hydrogen
  • L is C 1-10 alkylene
  • Q is a 5-10-membered heteroaryl group substituted by 1 or more Q 1-2 ;
  • Q 1-1 is C 1-4 alkyl or oxo
  • R is hydrogen
  • the C 1-10 alkylene group is a C 1-4 alkylene group (such as methylene, ethylene n-Propylene isopropylidene n-Butylidene isobutylene or tert-butylene N-propylene or n-butylene is preferred, and n-butylene is more preferred.
  • L is a C 2-10 alkenylene group
  • the C 2-10 alkenylene group is a C 2-4 alkenylene group
  • the -C 1-6 alkylene-C 3-6 cycloalkylene C 1-6 alkylene in the base is methylene, ethylene n-Propylene isopropylidene n-Butylidene isobutylene or tert-butylene Methylene or ethylene is preferred, and ethylene is more preferred.
  • the -C 1-6 alkylene-C 3-6 cycloalkylene C 3-6 cycloalkylene in the base is cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene (for example ), preferably
  • L is -C 1-6 alkylene-C 3-6 cycloalkylene-
  • the C 6-18 aryl group is a C 6-14 aryl group (such as phenyl, naphthyl, anthracenyl or phenanthrenyl) , and further can be phenyl.
  • the C 6-18 aryl group is a C 6-14 aryl group (such as phenyl, naphthyl, anthracenyl or phenanthryl), and further may be a phenyl group.
  • Q 1-1 when Q is a C 6-18 aryl group substituted by Q 1-1 , the number of Q 1-1 is one or two. When Q 1-1 is plural, Q 1-1 may be the same or different, eg, different.
  • the halogen is F, Cl, Br or I, preferably F.
  • the 5-10-membered heteroaryl group is a 9- or 10-membered heteroaryl group, and the number of heteroatoms is 1 or 2, more preferably
  • the 5-10-membered heteroaryl group is a 9- or 10-membered heteroaryl group
  • the heteroatom is N and/or O
  • the number is 1 or 2, preferably tetrahydroquinolinyl quinolinyl (e.g. ), benzoxazolyl (e.g. ), benzisoxazolyl (e.g. ) or tetrahydropyridopyrimidinyl (e.g. oxo ).
  • the number of Q 1-2 is one or two.
  • the Q 1-2s are the same or different, for example, different.
  • the C 1-4 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl.
  • R 1 and R 2 are independently 3-6 membered heterocycloalkyl
  • the 3-6 membered heterocycloalkyl is piperidinyl (for example, ) or pyrrolidinyl (eg ), preferably pyrrolidinyl.
  • R 1 and R 2 are independently C 6-18 aryl groups
  • the C 6-18 aryl groups are C 6-14 aryl groups (such as phenyl, naphthyl, anthracenyl or phenanthryl), and further may be a phenyl group.
  • R 1 and R 2 are independently a 5-10-membered heteroaryl group
  • the 5-10-membered heteroaryl group is a 9- or 10-membered heteroaryl group
  • the heteroatom is N
  • the number is 1 or 2, preferably indolyl (such as ).
  • R 1-1 , R 1-2 , R 1-3 and R 1-4 are independently C 1-4 alkyl
  • the C 1-4 alkyl is methyl methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, preferably methyl.
  • R is a C 1-4 alkyl group
  • the C 1-4 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl , sec-butyl or tert-butyl, preferably methyl.
  • L is C 1-10 alkylene group, C 2-10 alkenylene group or -C 1-6 alkylene group-C 3-6 cycloalkylene group.
  • L is C 1-10 alkylene or -C 1-6 alkylene-C 3-6 cycloalkylene.
  • M is -O-, -NH- or -CH 2 -.
  • Q 1-1 is halogen
  • R 1 is -NR 1-1 R 1-2 , 3-6-membered heterocycloalkyl, C 6-18 -membered aryl or 5-10-membered heteroaryl, preferably -NR 1 -1 R 1-2 , 3-6 membered heterocycloalkyl or C 6-18 aryl.
  • R is hydrogen
  • the compound shown in the formula I is optionally any of the following compounds:
  • the compound shown in the formula I is optionally any of the following compounds:
  • the compound shown in the formula I is optionally any of the following compounds:
  • optical rotation value is +50.33° and/or the retention time is 5.805min under the following chiral preparation conditions "or "with an optical rotation value of -45.00° and/or a retention time of 7.60min under the following chiral preparation conditions
  • the present invention also provides a preparation method of the above-mentioned compound shown in formula I, its pharmaceutically acceptable salt, its solvate or the solvate of its pharmaceutically acceptable salt, which comprises the following steps:
  • X is halogen; the definitions of L, M, Q and R are the same as above.
  • the conditions and operations of the alkylation reaction can be conventional conditions and operations of this type of reaction in the art, and the present invention particularly preferably the following conditions:
  • the basic reagent is, for example, K 2 CO 3 (for example, the molar ratio of the basic reagent to the compound of formula II is 6:1).
  • the solvent is, for example, tetrahydrofuran and dimethyl sulfoxide (for example, the volume ratio of the two is 3:1).
  • the temperature of the alkylation reaction is, for example, 60°C.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the above-mentioned compound shown in formula I, a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable salts thereof Accessories.
  • the present invention also provides the application of a substance A in the preparation of a dopamine D2 receptor agonist, wherein the substance A is the above-mentioned compound shown in formula I, a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate thereof.
  • the present invention also provides the application of a substance A in the preparation of a medicament for treating and/or preventing diseases related to dopamine D2 receptors;
  • the substance A is the above-mentioned compound shown in formula I, its pharmacy An acceptable salt, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described above.
  • the dopamine D2 receptor-related diseases refer to one or more of neurodegenerative diseases, mental disorders and metabolic diseases related to mental disorders, such as Parkinson's disease, Alzheimer's disease, Dementia, schizophrenia, bipolar disorder, depression, ADHD, restless legs syndrome, Huntington's disease, male erectile dysfunction, prolactinoma, or drug addiction.
  • neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Dementia, schizophrenia, bipolar disorder, depression, ADHD, restless legs syndrome, Huntington's disease, male erectile dysfunction, prolactinoma, or drug addiction.
  • the present invention also provides the application of a substance A in the preparation of a medicine for treating and/or preventing disease M;
  • the substance A is the above-mentioned compound shown in formula I, a pharmaceutically acceptable salt thereof, Its solvate or a solvate of a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition;
  • the disease M is a neurodegenerative disease, a mental disorder and a metabolic disease related to a mental disorder. one or more.
  • the disease M is preferably Parkinson's disease, Alzheimer's disease or dementia, schizophrenia, bipolar disorder, depression, ADHD, restless legs syndrome, Huntington's disease, male Erectile dysfunction, prolactinoma, or drug addiction.
  • the present invention also provides a method for preventing or treating a disease related to dopamine D2 receptors, which comprises administering to a subject a therapeutically effective amount of substance A, wherein the substance A is the above-mentioned compound represented by formula I, its A pharmaceutically acceptable salt, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition.
  • the dopamine D2 receptor-related diseases refer to one or more of neurodegenerative diseases, mental disorders and metabolic diseases related to mental disorders, such as Parkinson's disease, Alzheimer's disease, Dementia, schizophrenia, bipolar disorder, depression, ADHD, restless legs syndrome, Huntington's disease, male erectile dysfunction, prolactinoma, or drug addiction.
  • neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Dementia, schizophrenia, bipolar disorder, depression, ADHD, restless legs syndrome, Huntington's disease, male erectile dysfunction, prolactinoma, or drug addiction.
  • the present invention also provides a method for preventing or treating disease M, which comprises administering to a subject a therapeutically effective amount of substance A, wherein the substance A is the above-mentioned compound represented by formula I, a pharmaceutically acceptable Salt, its solvate or solvate of its pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition; said disease M is neurodegenerative disease, psychiatric disorders and metabolic diseases related to psychiatric disorders one or more of.
  • the disease M is preferably Parkinson's disease, Alzheimer's disease or dementia, schizophrenia, bipolar disorder, depression, ADHD, restless legs syndrome, Huntington's disease, male Erectile dysfunction, prolactinoma, or drug addiction.
  • substituents used may be preceded by a single dash "-" to indicate that the named substituent is attached to the parent moiety through a single bond. Additionally, substituents are described by conventional chemical formulae written in "left-to-right” or “top-to-bottom” writing conventions, for example, " -C1-6alkylene - C3-6cycloalkylene " Indicates that the C 1-6 alkylene group is attached to the N in the parent through a single bond.
  • compound and “pharmaceutically acceptable salt”, if tautomers exist, may exist as single tautomers or as mixtures thereof, preferably as more stable tautomers The main form exists.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • alkyl refers to a straight or branched chain alkyl group having the specified number of carbon atoms (eg, C1 - C10 ).
  • Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl Wait.
  • alkylene refers to a divalent group of a straight or branched chain saturated aliphatic hydrocarbon group having the specified number of carbon atoms.
  • Two valences can be concentrated on the same atom, e.g. methylene (-CH 2 -), ethylene
  • the two valences can also be attached to two atoms respectively, eg 1,2-ethylene ( -CH2CH2- ).
  • alkenylene refers to a divalent group having a specified number of carbon atoms (eg, C2 - C10 ), a straight or branched chain aliphatic hydrocarbon group containing one or more double bonds.
  • alkynylene refers to a divalent group having a specified number of carbon atoms (eg, C2 - C10 ), a straight or branched chain aliphatic hydrocarbon group containing one or more triple bonds.
  • Two valences can be concentrated on the same atom, e.g. Two valences can also be attached to two atoms respectively, for example
  • cycloalkyl refers to a saturated monocyclic cyclic group consisting of only carbon atoms having the specified number of carbon atoms (eg, C3 - C6 ). Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
  • cycloalkylene refers to a saturated cyclic alkylene divalent group, for example: cyclopentylene (eg or cyclohexylene, etc.).
  • heterocycloalkyl refers to a specified number of ring atoms (eg, 5-10 members), a specified number of heteroatoms (eg, 1, 2, or 3), a specified heteroatom species (N, O, and S) one or more of), which are monocyclic, bridged, or spirocyclic, and each ring is saturated.
  • Heterocycloalkyl groups include, but are not limited to, azetidinyl, tetrahydropyrrolyl, tetrahydrofuranyl, morpholinyl, piperidinyl, and the like.
  • aryl refers to a cyclic group consisting of only carbon atoms having a specified number of carbon atoms (eg C 6 -C 10 ), which is monocyclic or polycyclic, and at least one ring is aromatic ( complies with Huckel's rule).
  • Aryl groups are attached to other segments of the molecule through rings that are aromatic or non-aromatic.
  • Aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
  • heteroaryl refers to a specified number of ring atoms (eg, 5 to 10 members), a specified number of heteroatoms (eg, 1, 2, or 3), a specified species of heteroatoms (N, O, and S).
  • cyclic groups of which are monocyclic or polycyclic, and at least one ring is aromatic (complies with Huckel's rule).
  • Heteroaryl groups are attached to other moieties in the molecule through an aromatic ring or a non-aromatic ring.
  • Heteroaryl groups include, but are not limited to, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, and the like. Heteroaryl is also for example
  • a "-" at the end of a group means that the group is attached to other fragments in the molecule through that site.
  • any variable eg group R 1-1
  • their definitions are independent of each other and do not affect each other.
  • the C 6 -C 10 aryl group substituted by 3 R 1-1 means that the C 6 -C 10 aryl group will be substituted by 3 R 1-1 , and the definitions of the 3 R 1-1 are mutually independent and mutually exclusive. Does not affect.
  • pharmaceutically acceptable salt refers to a salt of a compound obtained by reacting a compound with a pharmaceutically acceptable (relatively non-toxic, safe, patient-friendly) acid or base.
  • base addition salts can be obtained by contacting the free form of the compound with a sufficient amount of a pharmaceutically acceptable base in a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include, but are not limited to, sodium, potassium, calcium, aluminum, magnesium, bismuth, ammonium, and the like.
  • acid addition salts can be obtained by contacting the free form of the compound with a sufficient amount of a pharmaceutically acceptable acid in a suitable inert solvent.
  • Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, sulfate, mesylate, and the like. See specifically Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl, 2002).
  • solvate refers to a substance formed upon crystallization of a compound with a solvent including, but not limited to, water, methanol, ethanol, and the like. Solvates are divided into stoichiometric and non-stoichiometric solvates.
  • solvate of a pharmaceutically acceptable salt refers to a compound with a pharmaceutically acceptable (relatively non-toxic, safe, suitable for patient use) acid or base, a solvent (including but not limited to: water, methanol, ethanol) etc.) are combined to form substances, wherein the pharmaceutically acceptable salt has the same meaning as the term “pharmaceutically acceptable salt” above and the solvent is stoichiometric or non-stoichiometric.
  • Solvates of pharmaceutically acceptable salts include, but are not limited to, hydrochloride monohydrate.
  • pharmaceutical excipients refers to the excipients and additives used in the production of pharmaceuticals and the formulation of prescriptions, and are all substances contained in pharmaceutical preparations other than active ingredients.
  • pharmaceutical excipients refers to the Pharmacopoeia of the People's Republic of China (2020 edition) or the Handbook of Pharmaceutical EMcipients (Raymond C Rowe, 2009).
  • treating refers to any of the following: (1) alleviating one or more biological manifestations of a disease; (2) interfering with one or more points in the biological cascade that causes the disease; (3) slowing the disease development of one or more biological manifestations.
  • prevention refers to reducing the risk of developing a disease.
  • patient refers to any animal, preferably a mammal, most preferably a human, who has been or is about to undergo treatment. Mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, and the like.
  • the reagents and raw materials used in the present invention are all commercially available.
  • the positive improvement effect of the present invention is that the compounds of the present invention have good affinity, agonistic activity or selectivity for dopamine D2 receptors.
  • Fig. 1 is an X-single crystal diffraction pattern of a crystal of the compound represented by pNs-(+)-I-10.
  • Human renal epithelial cells 293T were cultured in DMEM medium containing 10% fetal bovine serum (FBS), and the culture dish was placed at 37°C under the condition of 5% CO 2 . After the cells were fully attached to the culture dish, the culture medium was removed with a pipette, 1 mL of phosphate buffered saline (pH 7.4) was added to slowly wash to remove excess serum, and 800 ⁇ L of 0.25% trypsin was added to digest the cells in an incubator. For 2 min, take out the cells and observe under the microscope. The cells become round and swim freely at the bottom of the dish. Add 2 mL of culture medium containing 10% serum to terminate the digestion, and gently pipet the cells with a 1 mL gun to disperse them into single cells. Finally, according to the experimental needs Continue subculture or further experiments.
  • FBS fetal bovine serum
  • a 10 cm diameter dish was transfected with 10 ng of dopamine D2 receptor and 40 [mu]L PEI, and 48 hours later, the 10 cm dish in which the cultured cells had expressed the dopamine D2 receptor were removed from the cell chamber.
  • the culture medium was sucked off with a vacuum pump, 3 mL of lysis buffer (50 mM Tris hydrochloric acid buffer, pH 7.4) was added to each well, and the cells were placed in a cold storage at 4°C for 10 minutes. After the cells were detached, they were transferred to a 15 mL centrifuge tube, centrifuged at 1500 rpm in a 4°C centrifuge for 5 minutes, and the supernatant was discarded.
  • lysis buffer 50 mM Tris hydrochloric acid buffer, pH 7.4
  • the cell pellet was transferred to a tissue homogenizer, add 3 mL of lysate to it, and grind thoroughly until the cells are disrupted. Then, the cell suspension was aliquoted into multiple EP tubes, centrifuged at 12,000 rpm at 4°C for 5 min, and the supernatant was discarded. The precipitate is the cell membrane fraction containing dopamine D2 receptors, and is stored at -80°C.
  • Ligand receptor binding experiments were performed on 293T membrane fractions transiently expressing dopamine D2 receptors .
  • standard binding buffer 50 mM HEPES, 50 mM NaCl, 5 mM MgCl 2 , 0.5 mM EDTA, pH 7.4
  • 50 mM HEPES, 50 mM NaCl, 5 mM MgCl 2 , 0.5 mM EDTA, pH 7.4 was added to the cell membrane fraction containing dopamine D 2 receptors, and the cell membrane was disrupted and resuspended using an electric tissue homogenizer.
  • Add 30 ⁇ L of membrane protein suspension to each well of a 96-well plate.
  • Step 1 Add 7-hydroxy-3,4-dihydroquinolin-2(1H)-one (1.5g, 9.19mmol), 1,4-dibromobutane (5.92g, 27.6g) to the round-bottomed flask in turn mmol), K 2 CO 3 (1.9 g, 13.7 mmol) and solvent DMF (20 mL), the reaction system was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography (eluent: 20-50% ethyl acetate in ethyl acetate/petroleum ether mixture) to give intermediate wha71 (1.75 g, 64%), white solid.
  • Step 2 Intermediate A (50 mg, 0.23 mmol), intermediate wha71 (82 mg, 0.28 mmol) and K 2 CO 3 (0.2 g, 1.38 mmol) were added to the round-bottomed flask, followed by the solvent THF (3 mL) and DMSO (1 mL). The reaction system was heated and stirred at 60°C for 16 hours. After the reaction, the solvent was removed and purified by flash silica gel column chromatography (eluent: 0-10% methanol/dichloromethane) to give compound I-1 (90 mg, 91%) as an off-white solid.
  • Step 1 Following the method of Step 1 of Example 1, an alkylation reaction was carried out with "7-hydroxy-quinolin-2(1H)-one" and 1,4-dibromobutane as raw materials to prepare the intermediate wha70( 1.06 g, 38%), white solid.
  • Step 1 Following the method of Step 1 of Example 1, using "5-hydroxy-benzo[d]thiazole” and 1,4-dibromobutane as raw materials to prepare intermediate wha72 (1.23g, 65%), white solid .
  • 1 H NMR 800MHz, deuterated chloroform
  • ⁇ 8.98 s, 1H
  • Step 2 Following the method of Step 2 of Example 1, the intermediate wha72 was subjected to an alkylation reaction with the starting material (A) to obtain compound I-3 (30 mg, 51%) as a yellow solid.
  • 1 H NMR 800MHz, deuterated methanol
  • Step 1 Following the method of Step 1 of Example 1, using "2-methyl-5-hydroxy-benzo[d]thiazole" and 1,4-dibromobutane as raw materials to prepare intermediate whb35 (0.15g, 31 %), pale yellow solid.
  • Step 2 Following the method of Step 2 of Example 1, the intermediate whb35 was subjected to alkylation reaction with the raw material (A) to obtain compound I-4 (41 mg, 43%) as an off-white solid.
  • 1 H NMR 600 MHz, deuterated chloroform
  • Step 1 Following the method of Step 1 of Example 1, using "3-methyl-6-hydroxy-benzo[d]isoxazole” and 1,4-dibromobutane as raw materials to prepare intermediate whb37 (0.16 g , 42%), pale yellow solid.
  • Step 2 Following the method of Step 2 of Example 1, the intermediate whb37 was alkylated with the raw material (A) to obtain compound I-5 (58 mg, 60%) as an off-white solid.
  • 1 H NMR 600MHz, deuterated chloroform
  • ⁇ 8.03 s, 1H
  • 6.89(dd,J 8.7,2.4Hz,1H)
  • 6.77(d,J 8.1Hz,1H)
  • 6.32(d,J 7.6Hz,1H)
  • 4.02(t,J 6.3Hz,2H)
  • 3.79(d,J 12.0Hz,1H)
  • 3.21(t,J 10.8Hz,1H)
  • 2.81(dd,J
  • Step 1 Following the method of Step 1 of Example 1, using "6-hydroxy-2,3-dihydrobenzofuran" and 1,4-dibromobutane as raw materials to prepare intermediate whb53 (0.29g, 81%) , white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • Step 2 Following the method of Step 2 of Example 1, the intermediate wha53 was subjected to an alkylation reaction with the raw material (A) to obtain compound I-6 (30 mg, 32%) as a white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • Step 1 Following the method of Step 1 of Example 1, using "7-hydroxy-3,4-dihydroquinolin-2(1H)-one" and 1,3-dibromopropane as raw materials to prepare intermediate whb71 (2.85 g, 81%), white solid.
  • Step 2 Following the method of Step 2 of Example 1, the intermediate whb71 was subjected to an alkylation reaction with the starting material (A) to obtain compound I-7 (60 mg, 63%) as an off-white solid.
  • 1 H NMR 800MHz, deuterated chloroform
  • Step 1 Following the method of Step 1 of Example 1, using "7-hydroxy-quinolin-2(1H)-one" and 1,3-dibromopropane as raw materials to prepare intermediate whb73 (1.36g, 39%), White solid.
  • HR-MS (ESI, m/z): C 12 H 13 BrNO 2 + [M+H] + , calculated: 282.0124; found: 282.0128 and 284.0109 .
  • Step 2 Following the method of Step 2 of Example 1, the intermediate whb73 was subjected to an alkylation reaction with the raw material (A) to obtain compound I-8 (0.10 g, 51%) as a white solid.
  • 1 H NMR 600 MHz, deuterated methanol
  • Step 1 Following the method of Step 1 of Example 1, using sesamol (CAS#533-31-3) and 1,3-dibromopropane as raw materials, the intermediate whb74 (1.67g, 45%) was prepared as a white solid .
  • 1 H NMR 800MHz, deuterated chloroform
  • 4.02(t, J 5.8Hz, 2H)
  • Step 2 Following the method of Step 2 of Example 1, the intermediate whb74 and the raw material (A) were subjected to alkylation reaction to prepare compound I-9 (20 mg, 22%) as an off-white solid.
  • 1 H NMR 600 MHz, deuterated chloroform
  • Step 1 2-(4-((tert-butoxycarbonyl)amino)trans-cyclohexyl)acetic acid (2.0 g, 7.77 mmol), solvent DMF (15 mL) were added to the round-bottomed flask, followed by Cs 2 CO 3 (7.6 g, 23.3 mmol) and benzyl bromide BnBr (5.32 g, 11.7 mmol) and stirred at room temperature overnight. After the reaction was completed, it was filtered, the filtrate was concentrated, and the residue was purified by column chromatography (eluent: dichloromethane containing 0-20% methanol) to obtain the target compound whb52 (2.36 g, yield 87%) as a white solid.
  • solvent DMF 15 mL
  • Step 2 Dissolve whb52 (0.16 g, 0.46 mmol) in dichloromethane (3 mL) in the previous step, add trifluoroacetic acid (1.5 mL), and stir at room temperature for 3 hours. Concentrate under reduced pressure, dissolve the residue in THF (5 mL), then add Et3N (1 mL) followed by dimethylcarbamoyl chloride (54 mg, 0.5 mmol). The reaction system was stirred at room temperature overnight. After the reaction, the solvent was removed and purified by silica gel column chromatography (eluent: dichloromethane containing 0-20% methanol) to obtain the target compound whb54 (0.78 g, 83%) as a white solid.
  • Step 3 whb54 (0.78 g, 2.45 mmol) was dissolved in THF (20 mL), and the temperature was lowered to -10 °C under argon (Ar) protection. DABAL-H (14.7 mL, 1 M) was then added. The reaction system was then stirred for 5 hours at 0°C. After the reaction was complete, it was quenched with saturated sodium potassium tartrate solution (5 mL). After removal of solvent, silica gel column chromatography (eluent: 0-20% methanol in dichloromethane) afforded whb59 (0.50 g, 95% yield) as a white solid.
  • Step 4 Dissolve whb59 (0.65 g, 3.04 mmol) and CBr 4 (1.5 g, 4.56 mmol) in dichloromethane (15 mL), cool and stir in an ice-water bath. PPh3 (1.2 g, 4.56 mmol) was added, then moved to room temperature and stirred for 4 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (the mobile phase was dichloromethane containing 0-3% methanol) to obtain whb60 (0.25 g, 38%) as a white solid.
  • Step 5 The experimental method was the same as that of Step 2 of Example 1, and the alkylation reaction was carried out with whb60 and the raw material (A) to prepare compound I-10 (0.18 g, 95%) as an off-white solid.
  • (+)-I-10 (23mg, 0.056mmol) was dissolved in DMF (3mL), then potassium tert-butoxide (13mg, 0.116mmol) and p-nitrobenzenesulfonyl chloride (14mg, 0.063mmol) were added successively, The reaction solution was stirred at room temperature for one hour. After the reaction was completed, water was added, followed by extraction with dichloromethane solvent three times, and the organic phases were combined and concentrated. The crude product obtained by concentration was purified by flash silica gel column chromatography (eluent 0-10% methanol/dichloromethane) to give pNs-(+)-I-10 (20 mg, 60% yield) as an orange-yellow solid.
  • Cultivate single crystals by volatilization method Weigh 10 mg of compound pNs-(+)-I-10 product into 1 mL of chloroform, and then add 10 mL of petroleum ether. Place the test tube at room temperature and slowly evaporate the crystals.
  • the configuration of the compound pNs-(+)-I-10 can be determined from the characterization results of X-ray single crystal diffraction as Thus it can be deduced that the configuration of (+)-I-10 compound is Correspondingly, the configuration of the (-)-I-10 compound is
  • Step 1 Using whb52 as raw material, following the method of step 2 of Example 10, and replacing "dimethylcarbamoyl chloride” with “tetrahydropyrrole-1-carbonyl chloride", the intermediate whb77 (0.54 g, 87%) can be prepared ), white solid.
  • Step 2 Following the method of Step 3 of Example 10, whb77 was converted into whb81 (0.36 g, 96%), a white solid.
  • HR-MS (ESI, m/z): C 13 H 25 N 2 O 2 + [M+H] + , calculated: 241.1911; found: 241.1945.
  • Step 3 Following the method of Step 4 of Example 10, the intermediate whb81 was converted into whb87 (0.34 g, yield 76%), white solid.
  • 1 H NMR 600MHz, deuterated chloroform
  • ⁇ 3.99–3.93 m, 1H
  • 3.63–3.58 m, 1H
  • 3.32–3.29 m, 4H
  • 2.08–2.01(m,2H) 1.93–1.85(m,3H),1.83–1.73(m,4H),1.50–1.40(m,1H),1.17–1.02(m,4H).
  • Step 4 Following the method of Step 5 of Example 10, alkylation reaction of whb87 and raw material (A) was carried out to obtain the target compound I-11 (50 mg, 50%) as an off-white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • Step 1 Following the method of Step 2 of Example 10, substituting "piperidine-1-carbonyl chloride” for "dimethylcarbamoyl chloride", the intermediate whb80 can be prepared as a white solid.
  • 1 H NMR 800MHz, deuterated chloroform
  • HR-MS (ESI, m/z): C 16 H 29 N 2 O 3 + [M+H] + , calculated: 297.2173; Found: 297.2373.
  • Step 2 Following the method of Step 3 of Example 11, whb80 was converted into whb86, white solid.
  • 1 H NMR 800MHz, deuterated chloroform
  • HR-MS (ESI, m/z ): C14H27N2O2+ [M+H]+ , calcd : 255.2067 ; found: 255.2057.
  • Step 3 Following the method of Step 4 of Example 10, the intermediate whb86 was converted into whb89 (yield 80%), white solid.
  • 1 H NMR 600 MHz, deuterated chloroform
  • ⁇ 4.25 (s, 1H), 3.59 (s, 1H), 3.44 (t, J 7.0 Hz, 2H), 3.32–3.27 (m, 4H), 2.04–2.02 (m, 2H), 1.78–1.75 (m, 4H), 1.62–1.50 (m, 5H), 1.48–1.43 (m, 1H), 1.17–1.00 (m, 4H).
  • HR-MS (ESI, m/ z): C14H26BrN2O + [M + H] + , calcd: 317.1223 ; found: 317.1260 and 319.1141.
  • Step 4 Following the method of Step 5 of Example 10, alkylation reaction of whb89 and raw material (A) was carried out to obtain the target compound I-12 (62 mg, 98%) as a white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • Step 1 Add methyl 2-(4-aminotrans-cyclohexyl)acetate (0.19g, 1.02mmol) into tetrahydrofuran (5mL) into a round-bottomed flask, then add HATU (0.505g, 1.33mmol), DIPEA ( 1 mL) and 1H-indole-2-carboxylic acid (0.214 g, 1.33 mmol), the reaction system was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: 40-50% ethyl acetate in petroleum ether) to obtain intermediate whb108 (0.30 g, 90%) as a white solid.
  • Step 2 Following the method described in step 3 of Example 10, intermediate whb108 was reduced to obtain intermediate whb149 (80 mg, 47%) as a white solid.
  • HR-MS (ESI, m/z ): C17H23N2O2+ [M
  • Step 3 Following the method of Step 4 of Example 10, the alcohol intermediate whb149 was converted into the bromide whb150 (0.11 g, 45%), white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • Step 4 Following the method of Step 5 of Example 10, whb150 was alkylated with the raw material (A) to obtain compound I-13 (33 mg, yield 30%) as a white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • Step 1 Using "2-(4-((tert-butoxycarbonylaminotrans-cyclohexyl)ethyl acetate” as raw material, following the method of step 2 of Example 10, replace “dimethylamino acid” with “benzoyl chloride” formyl chloride” to give intermediate whb104 (0.20 g, yield 69%) as a white solid.
  • Step 2 Following the method described in Step 3 of Example 10, intermediate whb104 was reduced to obtain intermediate whb156 (0.11 g, yield 65%) as a white solid.
  • 1 H NMR 800MHz, deuterated chloroform
  • ⁇ 7.77–7.73 m, 2H
  • 7.51–7.46 m, 1H
  • 7.45–7.40 m, 2H
  • HR-MS (ESI, m/z): C 15 H 22 NO 2 + [M+H] + , Calculated value: 248.1645; Measured value: 248.1772.
  • Step 3 Following the method of Step 4 of Example 10, the alcohol intermediate whb156 was converted into the bromide whb158 (78 mg, 57%), white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • HR-MS (ESI, m/z): C 15 H 21 BrNO + [M+H] + , calculated: 310.0801; found: 310.0792 and 312.0
  • Step 4 Following the method of Step 5 of Example 10, whb158 was alkylated with the raw material (A) to obtain the target compound I-14 (30 mg, yield 32%) as a yellow solid.
  • 1 H NMR 800MHz, deuterated chloroform
  • ⁇ 7.84 s, 1H
  • 7.76–7.73 m, 2H
  • 7.52–7.46 m, 1H
  • 7.08(t,J 7.8Hz,1H)
  • Step 1 Using "2-(4-((tert-butoxycarbonylaminotrans-cyclohexyl)ethyl acetate” as raw material, following the method of step 2 of Example 10, replace “dimethylamino acid” with “benzenesulfonyl chloride” formyl chloride” to give intermediate whb105 (0.30 g, 89% yield) as a white solid.
  • Step 2 Following the method described in Step 3 of Example 10, intermediate whb105 was reduced to obtain intermediate whb155 (0.22 g, 87%) as a white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • ⁇ 7.90–7.86 m, 2H
  • 7.59–7.55 m, 1H
  • HR-MS (ESI, m/z): C 14 H 22 NO 3 S + [M+H] + , calculated: 284.1315; found: 284.133
  • Step 3 Following the method of Step 4 of Example 10, the alcohol intermediate whb155 was converted into the bromide whb159 (0.10 g, 37%), white solid.
  • 1 H NMR 800 MHz, deuterated chloroform
  • HR-MS (ESI, m/z): C14H21BrNO2S + [M + H] + , calcd: 346.0471 ; found: 346.0457 and 348.0435.
  • Step 4 Following the method of Step 5 of Example 10, whb159 was alkylated with the raw material (A) to obtain the target compound I-15 (40 mg, 98%) as a pale yellow solid.
  • Step 1 tert-butyl (4-(hydroxymethyl)trans-cyclohexyl)carbamate (0.23 g, 1 mmol) was dissolved in DMF (5 mL), followed by triethylamine (1 mL) and 4-nitrobenzene Sulfonyl chloride (0.27 g, 1.2 mmol) and the reaction was stirred at room temperature overnight. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane containing 0-10% methanol) to obtain intermediate whb132 (0.12 g, 29%) as a white solid.
  • Step 2 The intermediate whb132 (0.12 g, 0.29 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1.5 mL) was added, and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, concentrated under reduced pressure, the residue was dissolved in tetrahydrofuran (5 mL), then triethylamine (2 mL) and dimethylcarbamoyl chloride (37 mg, 0.35 mmol) were added, and the reaction system was stirred at room temperature overnight.
  • Step 3 Raw material (A) (50 mg, 0.23 mmol), intermediate whb133 (30 mg, 0.078 mmol) and K 2 CO 3 (127 mg, 0.92 mmol) were added to the round-bottomed flask, followed by the solvent tetrahydrofuran (3 mL) and dimethyl methane Sulfoxide (1 mL). The reaction system was heated and stirred at 60°C for 16 hours. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane containing 0-10% methanol) to obtain compound I-16 (12 mg, 13%) as an off-white solid.
  • Step 1 Raw material (A) (0.20 g, 0.94 mmol), triethylamine (0.4 g, 3.76 mmol), DMAP (12 mg, 0.094 mmol) and solvent DMF (5 mL) were added to a round-bottomed flask, and then Boc 2 O was added (0.23 g, 1.03 mmol) and stirred at room temperature for 12 hours. After the reaction, the solvent was removed by concentration under reduced pressure, and the residue was purified by silica gel column chromatography (eluent is dichloromethane containing 0-10% methanol) to obtain intermediate whb163 (0.22 g, 75%) as an off-white solid.
  • Step 4 The crude product obtained in Step 3 was dissolved in THF (3 mL), then DMSO (1.5 mL), K 2 CO 3 (0.12 g, 0.87 mmol) and the intermediate wha70 (49 mg, 0.17 mmol) described in Example 2 were added mmol), heated and stirred at 60 °C for 16 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane containing 0-10% methanol) to obtain the target compound I-18 (30 mg, 45%) as a pale yellow solid.
  • Step 1 Following the method of Step 1 of Example 1, using 7-hydroxy-3,4-dihydroquinolin-2(1H)-one and (E)-1,4-dibromo-2-butene as raw materials Alkylation was performed to prepare intermediate whc102 (0.82 g, 45%) as a yellow solid.
  • Step 2 Following the method of Step 2 of Example 1, the intermediate A was subjected to alkylation reaction with whc102 to obtain compound I-20 (40 mg, 33%) as a pale yellow solid.
  • Step 1 Following the method of Step 1 in Example 1, 7-hydroxy-quinolin-2(1H)-one and (E)-1,4-dibromo-2-butene were used as raw materials to carry out an alkylation reaction, Prepared intermediate whc72 (0.25 g, 14%) as a yellow solid.
  • Step 2 Following the method of Step 2 of Example 1, the intermediate A was alkylated with whc72 to obtain compound I-21 (50 mg, 51%) as an off-white solid.
  • Step 1 Cyclopropanyl (4-fluorophenyl) ketone (0.5 g, 3 mmol) and aqueous hydrobromic acid (3 mL) were added to a round-bottomed flask, and the reaction system was stirred at 80° C. for 2 hours. After the reaction was completed, it was cooled, water was added, and DCM was added for extraction three times. The organic phases were combined and concentrated under reduced pressure to give the crude product whc48 (0.73 g, 98%) as a yellow liquid.
  • Step 2 Following the method of Step 2 of Example 1, intermediate A and whc48 were alkylated to obtain compound I-24 (0.3 g, 57%) as a pale yellow solid.
  • Test Example 1 Affinity test of the compounds of the present invention for dopamine D2 receptors
  • the affinity of the compounds of the present invention for dopamine D2 receptors was determined by the method of radioligand competition.
  • cell membrane fractions containing specific dopamine D2 receptors are prepared. 10 cm dishes were transfected with 10 ng of dopamine D2 receptors and 40 [mu]L PEI, and 48 hours later, the 10 cm dishes in which the cultured cells had expressed dopamine D2 receptors were removed from the cell chamber. The culture medium was sucked off with a vacuum pump, 3 mL of lysis buffer was added to each well, and the cells were placed in a 4°C freezer for 10 minutes.
  • the cells were transferred to a 15 mL centrifuge tube, centrifuged at 1500 rpm in a 4°C centrifuge for 5 minutes, and the supernatant was discarded. Transfer the cell pellet to a tissue homogenizer, add 3 mL of lysate to it, and grind thoroughly until the cells are disrupted. Then, the cell suspension was aliquoted into multiple EP tubes, centrifuged at 12,000 rpm at 4°C for 5 min, and the supernatant was discarded. The precipitate is the cell membrane fraction containing dopamine D2 receptors. In the second step, ligand-receptor binding experiments were performed on 293T membrane fractions transiently expressing dopamine D2 receptors .
  • Example 3 Affinity test of the compounds of the present invention for 5-HT2A receptors
  • the affinity of the compounds of the present invention for 5-HT 2A receptors was determined by the method of radioligand competition.
  • cell membrane fractions containing specific 5-HT 2A receptors are prepared.
  • a 10 cm dish was transfected with 10 ng of 5-HT 2A receptor and 40 ⁇ L of PEI, and 48 hours later, a 10 cm dish in which the cultured cells had expressed 5-HT 2A receptor was removed from the cell chamber.
  • the culture medium was sucked off with a vacuum pump, 3 mL of lysis buffer was added to each well, and the cells were placed in a 4°C freezer for 10 minutes.
  • the cells were transferred to a 15 mL centrifuge tube, centrifuged at 1500 rpm in a 4°C centrifuge for 5 minutes, and the supernatant was discarded. Transfer the cell pellet to a tissue homogenizer, add 3 mL of lysate to it, and grind thoroughly until the cells are disrupted. Then, the cell suspension was aliquoted into multiple EP tubes, centrifuged at 12,000 rpm at 4°C for 5 min, and the supernatant was discarded. The precipitate is the cell membrane fraction containing the 5-HT 2A receptor. In the second step, ligand-receptor binding experiments were performed on 293T membrane fractions transiently expressing 5-HT 2A receptors.
  • the software of data acquisition and control system is Analyst1.5.1 software (Applied Biosystem).
  • the integration method of the sample peak in the spectrum is automatic integration; the ratio of the peak area of the sample and the peak area of the internal standard is used as an indicator, and the concentration of the sample is regressed.
  • Regression method linear regression, the weight coefficient is 1/X2.
  • Pharmacokinetic parameters were analyzed using WinNonlin Professional v6.3 (Pharsight, USA) with a non-compartmental model.
  • Cmax is the measured maximum blood drug concentration
  • the area under the blood drug concentration-time curve AUC(0 ⁇ t) is calculated by the trapezoidal method
  • Tmax is the peak time of the blood drug concentration after administration.
  • Test Example 4 Pharmacodynamic test of compound on schizophrenia-like animal behavioral model
  • NMDA antagonist MK801 the behavioral characterization of mice induced to produce hyperkinesia in an empty field environment was modeled to detect the effect of different compounds on the phenotype of MK801-induced hyperkinesia. inhibitory effect. All mouse behavioral experiments were carried out during the light period of the mice. The whole experiment was recorded by the camera, and the behavioral tracking software was used for automatic tracking and data statistics. The compound was administered by intraperitoneal injection. After the injection, the mice immediately entered the empty field and began to record the trajectory.
  • mice After 30 minutes, the mice received 0.2 mg/kg of MK801 by intraperitoneal injection and returned to the empty field immediately after administration. Continue to record the movement trajectory for 120 minutes. The cumulative moving distance of mice was counted as a data sampling point every five minutes. Data statistics were performed using Student-t-test, p ⁇ 0.05 was *, p ⁇ 0.01 was **, p ⁇ 0.001 was ***, and p ⁇ 0.0001 was ****. Table 7 shows the total moving distance of mice within 0-45 minutes under the combined action of different doses of (-)-I-10 and MK801 (0.2 mg/kg).
  • C57B6 mice were restrained for 5 hours to induce depression-related behavioral signs, and then the effects of compounds on their "depression-like" behaviors were detected by tail suspension and forced swimming experiments.
  • the specific experimental process is as follows. First, the mice were restrained with a mouse immobilizer for tail vein injection. During the restraint process, all behavioral abilities of the mice were restricted under the conditions of ensuring minimal pain to the mice. Mice were dosed by intraperitoneal injection before and after restraint. After the restraint, the mice returned to the rearing cage to recover for 30 minutes. After 30 minutes, mice in different groups were tested for their "depression-like" behavior by tail suspension or forced swimming.
  • Tail suspension experiment The tail tip of the mouse was fixed on the suspension rod of the iron frame by tape, and the mouse remained in the suspended position for 6 minutes. The first 2 minutes was the adaptation period, no data collection was performed, and the intermittent immobility behavior of the mice was time-recorded within the next 4 minutes. The length of time in this immobility state was used to measure the degree of behavioral despair in mice. Data statistics were performed using Student-t-test, p ⁇ 0.05 was *, p ⁇ 0.01 was **, p ⁇ 0.001 was ***, and p ⁇ 0.0001 was ****.
  • mice were placed in a 5L glass beaker filled with water, the water surface height was 15cm, and the mice needed to swim continuously in the beaker for 6 minutes. The first two minutes are the adaptation period, and no data collection will be performed.
  • the intermittent immobility behavior of the mice was time-recorded within the next four minutes, and the immobility behavior of the mice was defined as: the mice passively floated on the water surface without moving, and there were only small local movements required to maintain afloat. The length of time in this immobility state was used to measure the degree of behavioral despair in mice.
  • mice were injected intraperitoneally with 0.3 mg/kg MK801 twice a day to model cognitive impairment, and control mice were intraperitoneally injected with normal saline containing the same amount of DMSO. Mice were then rehabilitated in the rearing cages for seven days. After the recovery period, the mice were subjected to a new and old object recognition experiment to detect the effect of the compound on the cognitive ability of the mice.
  • mice were placed in the experimental field in advance, and they were acclimated to the environment in the low-light environment for one hour. After acclimatization, mice were administered by intraperitoneal injection. Thirty minutes after dosing, mice were placed into an empty field (40 cm in diameter of the empty field) pre-placed with two identical objects. Mice were free to explore in the empty field for 10 minutes, then removed from the empty field and returned to the rearing cage. After a one-hour interval, the mice returned to the empty field, pre-placed with an old object and a new object in the same position in the empty field. Mice were again free to explore in the empty field for 10 minutes.
  • the recognition time of mice for old and new objects was recorded separately and the recognition index was calculated.
  • the calculation method of the identification index is, (exploration time of new object - exploration time of old object)/(exploration time of new object + exploration time of old object).
  • Object exploration in mice was defined as object-facing sniffing, climbing, and direct contact. Data statistics were performed using Student-t-test, p ⁇ 0.05 was *, p ⁇ 0.01 was **, p ⁇ 0.001 was ***, and p ⁇ 0.0001 was ****.
  • the statistical results of the new and old object recognition indicators are shown in Table 9.
  • mice were injected intraperitoneally with 0.2 mg/kg MK801 twice a day to model cognitive impairment.
  • Control mice were intraperitoneally injected with normal saline containing the same amount of DMSO, and then the mice were subjected to the Morris water maze test. .
  • the experiments were carried out in a blue circular reservoir with a diameter of 130 cm.
  • the pool is filled with purified water about 30 cm deep.
  • the pool is divided into 4 fan-shaped areas by a cross, and the escape platform (diameter 6 cm) is located in the center of one of the fan-shaped areas, and is hidden 0.5 cm below the water surface.
  • the mouse entry position was fixed at the edges of the other three sectors.
  • the position of the water entry point is basically the same as the straight-line distance from the platform.
  • mice were dosed by intraperitoneal injection 30 minutes before the start of the experiment. After the experiment started, the mice were placed in the water with their heads facing the pool wall, and the placement position was randomly selected from one of the three starting positions of east, west, south, and west, and the underwater hidden platform was located in the northern quadrant. Record the time when the mouse finds the underwater platform. If the platform is not found within 1 minute, guide the mouse to the platform and let the mouse stay on the platform for 30 seconds. Then repeat the above steps 2 times from another starting point. Each animal was trained three times a day for 5 consecutive days.
  • Probe training The day after the last acquired training, the platform was removed and a 60-second probe training started. The animal was placed in the water from the opposite side of the original platform quadrant. The number of times the animal crossed the original platform position was recorded as an indicator of spatial memory. Data statistics were performed using Student-t-test, p ⁇ 0.05 was *, p ⁇ 0.01 was **, p ⁇ 0.001 was ***, and p ⁇ 0.0001 was ****. The water maze acquired training, and the results of daily platform exploration time are shown in Table 10.
  • the freezing behavior test showed that compound (-)-I-10 had no freezing-inducing effect in mice at 10 mg/kg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

一种氮杂麦角林类衍生物及其制备方法和应用，衍生物的结构如式(I)所示。氮杂麦角林类衍生物对多巴胺D2受体具有良好的亲和力、激动活性或者选择性。

Description

氮杂麦角林类衍生物及其制备方法和应用
本申请要求申请日为2021年2月1日的中国专利申请2021101382499和2021年9月29日的中国专利申请2021111530798的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明涉及一种氮杂麦角林类衍生物及其制备方法和应用。
背景技术
多巴胺能信号通路与人类的运动、行为、情绪、记忆等多种生理功能相关，是近几十年来神经生物学研究的焦点之一。多巴胺能信号通路的功能异常被认为是帕金森氏症、精神分裂症等多种疾病的发病原因。多巴胺能信号通路由神经递质多巴胺、多巴胺受体、以及与多巴胺受体相关联的下游信号分子组成。多巴胺受体属于G蛋白偶联受体(GPCR)超家族，是最为重要的中枢神经系统(CNS)药物靶标之一。多巴胺受体有五种亚型(D1-5)，其中D1、D5为D1类受体，主要与G s蛋白偶联，激活后升高细胞内cAMP水平；D2、D3、D4为D2类受体，主要与G i蛋白偶联，激活后降低细胞内cAMP水平。不同的多巴胺受体在中枢神经系统具有不同的表达水平和分布，发挥不同的生理功能(Martel与McArthur，Front Pharmacol 2020,11:1003)。
多巴胺受体的五种亚型中，对于D2受体的研究最为广泛和深入。临床在用药物如普拉克索(Pramipexole)、罗匹尼罗(Ropinirole)、罗替戈汀(Rotigotine)等，主要用于帕金森氏症和多动腿综合征的治疗，这些药物主要通过激活多巴胺D2受体发挥治疗作用，但对D3等其它多巴胺受体也有活性。抗精神分裂症药物如氟哌啶醇、奥氮平等主要通过拮抗D2受体发挥治疗作用，而最新一代的药物如阿立哌唑(aripiprazole)、卡利拉嗪(cariprazine)则为多巴胺D2受体的部分激动剂(Frankel与Schwartz，Ther Adv Psychopharmacol 2017,7(1):29-41)。
多巴胺D2受体与其它多巴胺受体，以及5-羟色胺(5-HT)受体等其它单胺类GPCR，在结构上均具有一定程度的同源性。这种同源性导致绝大多数的药物不具有靶点选择性。上述靶向多巴胺D2受体的大多数抗精神分裂症药物，对5-HT受体例如5-HT 2A受体，均具有一定程度的亲和力，部分药物对于5-HT 2A受体的亲和力甚至强于其对于D2受体的亲和力。D2受体和5-HT 2A受体的双重作用，是这些药物的共同特征。2018年，美国FDA批准上市的药物Pimavanserin，是5-HT 2A受体的选择性反向激动剂(Sahli与Tarazi，Expert Opin Drug Discov 2018,13(1):103-110)；2019年美国FDA批准上市的Lumateperone对5-HT 2A受体的亲和力也比D2受体高60倍左右(Blair,Drugs,2020,80(4),417-423)。然而，对D2受体具有高选择性的药物却很少见诸文献报道(Fan与Tan等人，Nat Comm,2020,11,1074)。
Krogsgaard-Larsen等人报导了一种氮杂麦角林骨架的化合物A，其衍生物A1具有5-HT 6受体的结合活性，衍生物A2具有多巴胺D2受体的激动活性，A3具有多巴胺D2受体的部分激动活性 (Krogsgaard-Larsen等，J.Med.Chem.2014,57,5823-5828；WO2011088836；WO2011088838)。这些化合物的靶点选择性、动物体内活性和其它成药性未见报导。
Figure PCTCN2022075094-appb-000001
发明内容
本发明所要解决的技术问题是现有的对多巴胺D2受体具亲和力、激动活性或者选择性的化合物种类较少，为此，本发明提供了一种氮杂麦角林类衍生物及其制备方法和应用。本发明的化合物对多巴胺D2受体具有良好的亲和力、激动活性或者选择性。
本发明提供了一种如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物：
Figure PCTCN2022075094-appb-000002
其中，L为C 1-10亚烷基、C 2-10亚烯基、C 2-10亚炔基或-C 1-6亚烷基-C 3-6亚环烷基-；
M为-O-、-NH-、-CH 2-、-(CH-OH)-或-C(＝O)-；
Q为C 6-18芳基、被1个或多个Q 1-1取代的C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；所述的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；所述的被1个或多个Q 1-2取代的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；
Q 1-1独立地为卤素或C 1-4烷基；
Q 1-2独立地为C 1-4烷基、氧代或羟基；
R 1和R 2独立地为-NR 1-1R 1-2、3-6元杂环烷基、C 6-18芳基、被1个或多个R 1-3取代的C 6-18芳基、5-10元杂芳基或被1个或多个R 1-4取代的5-10元杂芳基；所述的3-6元杂环烷基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；所述的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；所述的被1个或多个R 1-4取代的5-10元杂芳基中的杂原子 为N、S或O中的一种或多种，个数为1个、2个或3个；
R 1-1、R 1-2、R 1-3和R 1-4独立地为C 1-4烷基；
R为氢或C 1-4烷基。
在某一优选技术方案中，所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物中，某些基团的定义可如下所述，其余基团的定义如本发明任一方案所述，以下简称为“在某一优选技术方案中”。
在某一优选技术方案中，所述的如式I所示的化合物为如式Ia、Ib或Ic所示的化合物：
Figure PCTCN2022075094-appb-000003
式Ic中，
Figure PCTCN2022075094-appb-000004
表示双键或单键；Y为氢、羟基或氧。
在某一优选技术方案中，所述的如式I所示的化合物为如式Id和/或Ie所示的化合物，优选如式Id所示的化合物；
Figure PCTCN2022075094-appb-000005
在某一优选技术方案中，当所述的如式I所示的化合物仅在
Figure PCTCN2022075094-appb-000006
中具有一个手性中心时，
Figure PCTCN2022075094-appb-000007
为
Figure PCTCN2022075094-appb-000008
和/或
Figure PCTCN2022075094-appb-000009
优选
Figure PCTCN2022075094-appb-000010
其中，“*”标记的碳原子为手性碳原子；(+)表示右旋的化合物，(-)表示左旋的化合物。
在某一优选技术方案中，
L为C 1-10亚烷基、C 2-10亚烯基或-C 1-6亚烷基-C 3-6亚环烷基-；
当M为-(CH-OH)-或-C(＝O)-时，R为氢。
在某一优选技术方案中，
L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
M为-O-、-NH-或-CH 2-；
Q为C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2。
在某一优选技术方案中，
L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
M为-O-、-NH-或-CH 2-；
Q为C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；
当M为-O-时，Q 1-2为C 1-4烷基或羟基；
当所述的5-10元杂芳基中的杂原子为O时，所述的5-10元杂芳基中杂原子的个数为1个。
在某一优选技术方案中，
L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
M为-O-、-NH-或-CH 2-；
Q为C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；
当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基-中的C 1-6亚烷基为亚乙基。
在某一优选技术方案中，
L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
M为-O-或-NH-；
Q为-C(＝O)R 1或被1个或多个Q 1-2取代的5-10元杂芳基；
R 1为-NR 1-1R 1-2。
在某一优选技术方案中，L为C 1-10亚烷基；
M为-O-；
Q为被1个或多个Q 1-2取代的5-10元杂芳。
在某一优选技术方案中，L为-C 1-6亚烷基-C 3-6亚环烷基-；
M为-NH-；
Q为-C(＝O)R 1；
R 1为-NR 1-1R 1-2。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ia所示：
Figure PCTCN2022075094-appb-000011
L为C 1-10亚烷基或C 2-10亚烯基；
Q为5-10元杂芳基、或、被1个或多个Q 1-2取代的5-10元杂芳基。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ia所示：
Figure PCTCN2022075094-appb-000012
L为C 1-10亚烷基或C 2-10亚烯基；
Q为被1个或多个Q 1-1取代的C 6-18芳基、5-10元杂芳基、或、被1个或多个Q 1-2取代的5-10元杂芳基；
Q 1-1为卤素。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ib所示：
Figure PCTCN2022075094-appb-000013
L为-C 1-6亚烷基-C 3-6亚环烷基-；
Q为-C(＝O)R 1或-S(＝O) 2R 2；
R 1和R 2独立地为-NR 1-1R 1-2、3-6元杂环烷基、C 6-18芳基或5-10元杂芳基。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ic所示：
Figure PCTCN2022075094-appb-000014
Figure PCTCN2022075094-appb-000015
表示双键或单键；
Y为氢、羟基或氧；
L为C 1-10亚烷基；
Q为被1个或多个Q 1-1取代的C 6-18芳基、或、被1个或多个Q 1-2取代的5-10元杂芳基；
Q 1-1为卤素；
Q 1-2独立地为C 1-4烷基或氧代。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ic-1所示：
Figure PCTCN2022075094-appb-000016
L为C 1-10亚烷基；
Q为被1个或多个Q 1-1取代的C 6-18芳基；
Q 1-1为卤素；
R为氢。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ic-2所示：
Figure PCTCN2022075094-appb-000017
L为C 1-10亚烷基；
Q为被1个或多个Q 1-1取代的C 6-18芳基；
Q 1-1为卤素；
R为氢。
在某一优选技术方案中，所述的如式I所示的分子结构为如式Ic-3所示：
Figure PCTCN2022075094-appb-000018
L为C 1-10亚烷基；
Q为被1个或多个Q 1-2取代的5-10元杂芳基；
Q 1-1为C 1-4烷基或氧代；
R为氢。
在某一优选技术方案中，当L为C 1-10亚烷基时，所述的C 1-10亚烷基为C 1-4亚烷基(例如亚甲基、亚乙基
Figure PCTCN2022075094-appb-000019
亚正丙基
Figure PCTCN2022075094-appb-000020
亚异丙基
Figure PCTCN2022075094-appb-000021
亚正丁基
Figure PCTCN2022075094-appb-000022
亚异丁基
Figure PCTCN2022075094-appb-000023
或亚叔丁基
Figure PCTCN2022075094-appb-000024
优选亚正丙基或亚正丁基，更优选为亚正丁基。
在某一优选技术方案中，当L为C 2-10亚烯基，所述的C 2-10亚烯基为C 2-4亚烯基时，优选为
Figure PCTCN2022075094-appb-000025
在某一优选技术方案中，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的C 1-6亚烷基与N相连接，所述的C 3-6亚环烷基与Q相连接。
在某一优选技术方案中，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基中C 1-6亚烷基为亚甲基、亚乙基
Figure PCTCN2022075094-appb-000026
亚正丙基
Figure PCTCN2022075094-appb-000027
亚异丙基
Figure PCTCN2022075094-appb-000028
亚正丁基
Figure PCTCN2022075094-appb-000029
亚异丁基
Figure PCTCN2022075094-appb-000030
或亚叔丁基
Figure PCTCN2022075094-appb-000031
优选亚甲基或亚乙基，更优选为亚乙基。
在某一优选技术方案中，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基中C 3-6亚环烷基为亚环丙基、亚环丁基、亚环戊基或亚环己基(例如
Figure PCTCN2022075094-appb-000032
)，优选为
Figure PCTCN2022075094-appb-000033
在某一优选技术方案中，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基-为
Figure PCTCN2022075094-appb-000034
(例如
Figure PCTCN2022075094-appb-000035
)或
Figure PCTCN2022075094-appb-000036
(例如
Figure PCTCN2022075094-appb-000037
)，其中a端与Q相连接，b端与N相连接，优选
Figure PCTCN2022075094-appb-000038
在某一优选技术方案中，当Q为C 6-18芳基时，所述的C 6-18芳基为C 6-14的芳基(例如苯基、萘基、蒽基或菲基)，进一步可以为苯基。
在某一优选技术方案中，当Q为Q 1-1取代的C 6-18芳基时，所述的C 6-18芳基为C 6-14的芳基(例如苯基、萘基、蒽基或菲基)，进一步可以为苯基。
在某一优选技术方案中，当Q为Q 1-1取代的C 6-18芳基时，所述的Q 1-1为1个或2个。当Q 1-1为多个时，Q 1-1可相同或不同，例如不同。
在某一优选技术方案中，当Q 1-1为卤素时，所述的卤素为F、Cl、Br或I，优选为F。
在某一优选技术方案中，当Q为Q 1-1取代的C 6-18芳基时，所述的Q 1-1取代的C 6-18芳基为
Figure PCTCN2022075094-appb-000039
在某一优选技术方案中，当Q为5-10元杂芳基时，所述的5-10元杂芳基为9或10元杂芳基，杂原子个数为1个或2个，进一步优选为
Figure PCTCN2022075094-appb-000040
在某一优选技术方案中，当Q为被1个或多个Q 1-2取代的5-10元杂芳基时，所述的5-10元杂芳基为9或10元杂芳基，杂原子为N和/或O，个数为1个或2个，优选为四氢喹啉基
Figure PCTCN2022075094-appb-000041
喹啉基(例如
Figure PCTCN2022075094-appb-000042
)、苯并噁唑基(例如
Figure PCTCN2022075094-appb-000043
)、苯并异噁唑基(例如
Figure PCTCN2022075094-appb-000044
)或四氢吡啶并嘧啶基(例如氧代的
Figure PCTCN2022075094-appb-000045
)。
在某一优选技术方案中，当Q为Q 1-2取代的C 6-18芳基时，所述的Q 1-2为1个或2个。当所述的Q 1-2为多个时，所述的Q 1-2相同或不同，例如不同。
在某一优选技术方案中，当Q 1-2为C 1-4烷基时，所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基，优选为甲基。
在某一优选技术方案中，当Q为被1个或多个Q 1-2取代的5-10元杂芳基时，所述的被1个或多 个Q 1-2取代的5-10元杂芳基为
Figure PCTCN2022075094-appb-000046
Figure PCTCN2022075094-appb-000047
在某一优选技术方案中，当R 1和R 2独立地为3-6元杂环烷基时，所述的3-6元杂环烷基为哌啶基(例如
Figure PCTCN2022075094-appb-000048
)或吡咯烷基(例如
Figure PCTCN2022075094-appb-000049
)，优选为吡咯烷基。
在某一优选技术方案中，当R 1为3-6元杂环烷基时，所述的3-6元杂环烷基通过杂原子与羰基相连接。
在某一优选技术方案中，当R 1和R 2独立地为C 6-18芳基时，所述的C 6-18芳基为C 6-14的芳基(例如苯基、萘基、蒽基或菲基)，进一步可以为苯基。
在某一优选技术方案中，当R 1和R 2独立地为被1个或多个R 1-3取代的C 6-18芳基时，所述的C 6- 18芳基为C 6-14的芳基(例如苯基、萘基、蒽基或菲基)，进一步可以为苯基。
在某一优选技术方案中，当R 1和R 2独立地为5-10元杂芳基时，所述的5-10元杂芳基为9或10元杂芳基，杂原子为N，个数为1个或2个，优选为吲哚基(例如
Figure PCTCN2022075094-appb-000050
)。
在某一优选技术方案中，当R 1-1、R 1-2、R 1-3和R 1-4独立地为C 1-4烷基时，所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基，优选为甲基。
在某一优选技术方案中，当R为C 1-4烷基时，所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基，优选为甲基。
在某一优选技术方案中，L为C 1-10亚烷基、C 2-10亚烯基或-C 1-6亚烷基-C 3-6亚环烷基。
在某一优选技术方案中，L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基。
在某一优选技术方案中，M为-O-、-NH-或-CH 2-。
在某一优选技术方案中，Q 1-1为卤素。
在某一优选技术方案中，R 1为-NR 1-1R 1-2、3-6元杂环烷基、C 6-18芳基或5-10元杂芳基，优选为-NR 1-1R 1-2、3-6元杂环烷基或C 6-18芳基。
在某一优选技术方案中，R为氢。
在某一优选技术方案中，
Figure PCTCN2022075094-appb-000051
为
Figure PCTCN2022075094-appb-000052
Figure PCTCN2022075094-appb-000053
在某一优选技术方案中，所述的如式I所示的化合物任选如下任一化合物：
Figure PCTCN2022075094-appb-000054
Figure PCTCN2022075094-appb-000055
在某一优选技术方案中，所述的如式I所示的化合物任选如下任一化合物：
Figure PCTCN2022075094-appb-000056
在某一优选技术方案中，所述的如式I所示的化合物任选如下任一化合物：
“旋光值为+50.33°和/或在如下手性制备条件下保留时间为5.805min的
Figure PCTCN2022075094-appb-000057
”或“旋光值为-45.00°和/或在下述手性制备条件下保留时间为7.60min的
Figure PCTCN2022075094-appb-000058
所述的手性制备条件：色谱柱：手性柱CHIRALCEL OD，柱体积：5.0cmx 25cm，10μm填料；流动相：MeOH/二乙胺＝100/0.1；流速：30mL/min；波长：UV 214nm；温度：38℃。
在某一优选技术方案中，所述的如式I所示的化合物为如下化合物：
Figure PCTCN2022075094-appb-000059
本发明还提供一种上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物的制备方法，其包括以下步骤：
在碱性试剂存在下，将如式II所示的化合物与如式III所示的化合物在溶剂中进行如下所示的烷基化反应，得到如式I所示的化合物；
Figure PCTCN2022075094-appb-000060
其中，X为卤素；L、M、Q和R的定义均同前所述。
所述的烷基化反应的条件和操作可为本领域此类反应常规的条件和操作，本发明特别优选以下条件：
所述的碱性试剂例如为K 2CO 3(例如碱性试剂与式II化合物的摩尔比为6:1)。
所述的溶剂例如为四氢呋喃和二甲亚砜(例如二者体积比为3:1)。
所述的烷基化反应的温度例如为60℃。
本发明还提供一种上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物的制备方法，其包括以下步骤：
在碱性试剂存在下，将如式II所示的化合物与如式III所示的化合物在
本发明还提供了一种药物组合物，其包括上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物和药用辅料。
本发明还提供了一种物质A在制备多巴胺D2受体激动剂的应用，所述的物质A为上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物或上述的药物组合物。
本发明还提供了一种物质A在制备用于治疗和/或预防与多巴胺D2受体相关疾病的药物中的应用；所述的物质A为上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物或上述的药物组合物。
所述的与多巴胺D2受体相关疾病指神经退行性疾病、精神异常类疾病和与精神异常类相关的代 谢性疾病中的一种或多种，例如帕金森氏症、阿尔茨海默症、痴呆症、精神分裂症、双向情感障碍、抑郁症、多动症、不安腿综合症、亨廷顿舞蹈症、男性勃起障碍、泌乳素瘤或毒品成瘾。
本发明还提供了一种物质A在制备用于治疗和/或预防疾病M的药物中的应用；所述的物质A为上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物或上述的药物组合物；所述的疾病M为神经退行性疾病、精神异常类疾病和与精神异常类相关的代谢性疾病中的一种或多种。
所述的应用中，所述的疾病M优选为帕金森氏症、阿尔茨海默症或痴呆症、精神分裂症、双向情感障碍、抑郁症、多动症、不安腿综合症、亨廷顿舞蹈症、男性勃起障碍、泌乳素瘤或毒品成瘾。
本发明还提供了一种预防或治疗与多巴胺D2受体相关疾病的方法，其包括给予受试者治疗有效量的物质A，所述的物质A为上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物或上述的药物组合物。
所述的与多巴胺D2受体相关疾病指神经退行性疾病、精神异常类疾病和与精神异常类相关的代谢性疾病中的一种或多种，例如帕金森氏症、阿尔茨海默症、痴呆症、精神分裂症、双向情感障碍、抑郁症、多动症、不安腿综合症、亨廷顿舞蹈症、男性勃起障碍、泌乳素瘤或毒品成瘾。
本发明还提供了一种预防或治疗疾病M的方法，其包括给予受试者治疗有效量的物质A，所述的物质A为上述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物或上述的药物组合物；所述的疾病M为神经退行性疾病、精神异常类疾病和与精神异常类相关的代谢性疾病中的一种或多种。
所述的方法中，所述的疾病M优选为帕金森氏症、阿尔茨海默症或痴呆症、精神分裂症、双向情感障碍、抑郁症、多动症、不安腿综合症、亨廷顿舞蹈症、男性勃起障碍、泌乳素瘤或毒品成瘾。
本发明还提供一种如式pNs-(+)-I-10所示的晶体，其晶系属于三斜晶系，P1空间群，晶胞参数为
Figure PCTCN2022075094-appb-000061
α＝90.15°，β＝99.368°，γ＝90.25°；
Figure PCTCN2022075094-appb-000062
如无特别说明，本发明所用术语具有如下含义：
本文中，所用的取代基前面可以加单破折号“-”，表明被命名取代基与母体部分之间通过单键相连。此外，通过“从左到右”或“从上到下”书写习惯书写的常规化学式来描述取代基，举例而言，“-C 1- 6亚烷基-C 3-6亚环烷基”表示C 1-6亚烷基与母体中的N通过单键相连。
术语“化合物”和“药学上可接受的盐”如存在互变异构体，则可以以单一的互变异构体或它们的混合物的形式存在，较佳地以较稳定的互变异构体为主的形式存在。
术语“卤素”是指氟、氯、溴或碘。
术语“烷基”是指具有指定的碳原子数(例如C 1～C 10)的直链或支链烷基。烷基包括但不限于甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、正戊基、正己基、正庚基、正辛基等。
术语“亚烷基”是指具有指定的碳原子数的直链或支链的饱和脂族烃基的二价基团。两个价可集中在同一个原子上，例如亚甲基(-CH 2-)、亚乙基
Figure PCTCN2022075094-appb-000063
两个价还可以分别连在两个原子上，例如1,2-亚乙基(-CH 2CH 2-)。
术语“亚烯基”是指具有指定的碳原子数(例如C 2-C 10)的、含有一个或多个双键的直链或支链的脂族烃基的二价基团。两个价可集中在同一个原子上，例如
Figure PCTCN2022075094-appb-000064
两个价还可以分别连在两个原子上，例如-CH 2CH＝CHCH 2-。
术语“亚炔基”是指具有指定的碳原子数(例如C 2～C 10)的、含有一个或多个叁键的直链或支链的脂族烃基的二价基团。两个价可集中在同一个原子上，例如
Figure PCTCN2022075094-appb-000065
两个价还可以分别连在两个原子上，例如
Figure PCTCN2022075094-appb-000066
术语“环烷基”是指具有指定的碳原子数(例如C 3～C 6)的、仅由碳原子组成的、饱和的单环环状基团。环烷基包括但不限于环丙基、环丁基、环戊基、环己基等。
术语“亚环烷基”是指饱和的环状亚烷基的二价基团，举例而言：亚环戊基(例如
Figure PCTCN2022075094-appb-000067
Figure PCTCN2022075094-appb-000068
或亚环己基等)。
术语“杂环烷基”是指具有指定环原子数(例如5～10元)的、指定杂原子数(例如1个、2个或3个)的、指定杂原子种类(N、O和S中的一种或多种)的环状基团，其为单环、桥环或螺环，且每一个环均为饱和的。杂环烷基包括但不限于氮杂环丁烷基、四氢吡咯基、四氢呋喃基、吗啉基、哌啶基等。
术语“芳基”是指具有指定的碳原子数(例如C 6～C 10)的、仅由碳原子组成的环状基团，其为单环或多环，且至少一个环具有芳香性(符合休克尔规则)。芳基通过具有芳香性的环或不具有芳香性的环与分子中的其他片段连接。芳基包括但不限于苯基、萘基等。
术语“杂芳基”是指具有指定环原子数(例如5～10元)的、指定杂原子数(例如1个、2个或3个)的、指定杂原子种类(N、O和S中的一种或多种)的环状基团，其为单环或多环，且至少一个环具有芳香性(符合休克尔规则)。杂芳基通过具有芳香性的环或不具有芳香性的环与分子中的其他 片段连接。杂芳基包括但不限于呋喃基、吡咯基、噻吩基、吡唑基、咪唑基、噁唑基、噻唑基、吡啶基、嘧啶基、吲哚基等。杂芳基还例如
Figure PCTCN2022075094-appb-000069
基团末端的“-”是指该基团通过该位点与分子中的其他片段连接。例如，CH 3-C(＝O)-是指乙酰基。
结构片段中的
Figure PCTCN2022075094-appb-000070
是指该结构片段通过该位点与分子中的其他片段连接。例如，
Figure PCTCN2022075094-appb-000071
是指环己基。
术语“多个”是指2个、3个、4个或5个。
当任意变量(例如基团R 1-1)在化合物的定义中多次出现时，它们的定义互相独立、互不影响。例如，被3个R 1-1取代的C 6～C 10芳基是指C 6～C 10芳基会被3个R 1-1取代，3个R 1-1的定义互相独立的、互不影响。
术语“药学上可接受的盐”是指化合物与药学上可接受的(相对无毒、安全、适合于患者使用)酸或碱反应得到的盐。当化合物中含有相对酸性的官能团时，可以通过在合适的惰性溶剂中用足量的药学上可接受的碱与化合物的游离形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括但不限于钠盐、钾盐、钙盐、铝盐、镁盐、铋盐、铵盐等。当化合物中含有相对碱性的官能团时，可以通过在合适的惰性溶剂中用足量的药学上可接受的酸与化合物的游离形式接触的方式获得酸加成盐。药学上可接受的酸加成盐包括但不限于盐酸盐、硫酸盐、甲磺酸盐等。具体参见Handbook of Pharmaceutical Salts:Properties,Selection,and Use(P.Heinrich Stahl,2002)。
术语“溶剂合物”是指化合物与溶剂(包括但不限于：水、甲醇、乙醇等)结晶后形成的物质。溶剂合物分为化学计量类溶剂合物和非化学计量类溶剂合物。
术语“药学上可接受的盐的溶剂合物”是指化合物与药学上可接受的(相对无毒、安全、适合于患者使用)酸或碱、溶剂(包括但不限于：水、甲醇、乙醇等)结合形成的物质，其中，药学上可接受的盐与上文术语“药学上可接受的盐”的含义相同，溶剂为化学计量的或非化学计量的。药学上可接受的盐的溶剂合物包括但不限于盐酸盐一水合物。
术语“药用辅料”是指生产药品和调配处方时使用的赋形剂和附加剂，是除活性成分以外，包含在药物制剂中的所有物质。具体参见中华人民共和国药典(2020年版)或Handbook of Pharmaceutical EMcipients(Raymond C Rowe,2009)。
术语“治疗”是指下述任一情形：(1)缓解疾病的一种或多种生物学表现；(2)干扰引发疾病的生物级联中的一个或多个点；(3)减缓疾病的一种或多种生物学表现发展。
术语“预防”是指降低发生疾病的风险。
术语“患者”是指已经或即将接受治疗的任何动物，优选哺乳动物，最优选人类。哺乳动物包括但不限于牛、马、羊、猪、猫、狗、小鼠、大鼠、家兔、豚鼠、猴、人类等。
在不违背本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于：本发明的化合物具有良好的对多巴胺D2受体的亲和力、激动活性或选择性。
附图说明
图1为pNs-(+)-I-10所示的化合物的晶体的X-单晶衍射图。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
材料和方法
1、细胞培养
人肾上皮细胞293T培养在含有10％胎牛血清(FBS)的DMEM培养液中，培养皿置于37℃，5％CO 2条件下进行培养。待细胞贴满培养皿后，用移液枪吸走培养液，加入1mL磷酸盐缓冲液(pH 7.4)缓慢清洗去除多余的血清，后加入800μL 0.25％胰酶，将细胞置于恒温箱中消化2min，取出细胞于显微镜下观察，细胞变圆并在皿底自由游动，加入2mL含有10％血清的培养液终止消化，用1mL枪轻轻吹打细胞使之分散成为单细胞，最后按照实验需要继续传代培养或者进一步实验。
2、细胞转染
转染前一天，直径10厘米的培养皿中长满的293T细胞以1：4分到6厘米培养皿中进行传代。20小时后，待细胞密度达到50％-70％时，准备转染。取500μL 150mM氯化钠于干净EP管中，向其中加入适量质粒，同时，转染试剂PEI以质粒的4倍量加入到其中，充分混匀。室温孵育20分钟。500μL转染溶液悬空滴加到培养皿中，轻轻摇动使之混匀。
3、含有特定多巴胺D 2受体的细胞膜组分制备
直径10厘米的培养皿以10ng多巴胺D 2受体和40μL PEI进行转染，48小时后，从细胞房拿出10厘米培养皿，其中培养的细胞已表达多巴胺D 2受体。用真空泵吸掉培养液，每孔加入3mL裂解液(50mM Tris盐酸缓冲液，pH 7.4)，将细胞置于4℃冷库，静置10分钟。待细胞脱落后，将其转移到15mL离心管中，4℃离心机1500rpm离心5分钟，弃上清。将细胞沉淀转移到组织匀浆器中，再向其中加入3mL裂解液，充分研磨至细胞破碎。然后，将细胞悬液等分至多个EP管中，4℃离心机12000rpm离心5min，弃上清。沉淀即为含有多巴胺D2受体的细胞膜组分，-80℃保存。
4、放射性配体受体结合实验
对瞬时表达多巴胺D 2受体的293T膜组分进行配体受体结合实验。首先，向含有多巴胺D 2受体的细胞膜组分加入标准结合缓冲液(50mM HEPES,50mM NaCl,5mM MgCl 2,0.5mM EDTA,pH 7.4)，用电动组织匀浆器将细胞膜破碎重悬。96孔板每孔加入30μL膜蛋白悬液。然后，96孔板从左到右 依次加入30μL不同药物，保证药物终浓度由下到上依次为10 -5M、10 -6M、10 -7M、10 -8M、10 -9M、0M，每种处理两个重复。紧接着，96孔板每孔加入30μL[ 3H]-N-Methylspiperone,室温避光孵育2小时。利用Whatman GF/C滤膜和真空泵去除未结合的同位素，后利用MicroBeta同位素液闪仪检测结合受体的同位素。
5、基于生物发光共振能量转移(BRET)的G蛋白Gαi1-γ9解离实验
为了检测多巴胺D 2受体介导的下游G蛋白信号通路，6厘米培养皿以1μg多巴胺D 2受体、1μg融合海藻荧光素酶的Gα i1(Gα i1-Rluc)、1μg Gβ 3、1μg融合绿色荧光蛋白的Gγ 9(Gγ 9-GFP)和16μL转染试剂PEI进行转染。第二天，利用0.25％胰酶消化长满的细胞，以一个长满细胞的6厘米培养皿细胞量铺一个96孔板，每孔100μL培养液。第三天，加药检测。从细胞房中拿出96孔板去除培养液，每孔加入40μL缓冲液(1X HBSS，20mM HEPES，pH 7.4)含底物腔肠素400a(7.5μM)，紧接着从左到右依次加入20μL不同的药物，保证药物终浓度由下到上梯度递减，每种处理两个重复。利用LB940Mithras plate reader(Berthold Technologies)检测395纳米和510纳米读值，以510纳米值和395纳米值的比值作为最终值。
6、基于生物发光共振能量转移(BRET)的β-arrestin2招募实验
为了检测多巴胺D 2受体介导的下游β-arrestin2信号通路，6厘米培养皿以500μg融合海藻荧光素酶的多巴胺D 2受体(D 2-Rluc)、500μg G蛋白偶联受体激酶2(GRK2)、2500μg融合绿色荧光蛋白的β-arrestin2(GFP2-ARRB2)和14μL转染试剂PEI进行转染。第二天，消化长满的细胞，以一个长满细胞的6厘米培养皿细胞量铺一个96孔板，每孔100μL培养液。第三天，加药检测。从细胞房中拿出96孔板去除培液，每孔加入40μL缓冲液(1X HBSS，20mM HEPES，pH 7.4)含底物腔肠素400a(7.5μM)，紧接着从左到右依次加入20μL不同的药物，保证药物终浓度由下到上梯度递减，每种处理两个重复。利用LB940Mithras plate reader(Berthold Technologies)检测395纳米和510纳米读值，以510纳米值和395纳米值的比值作为最终值。
原料(A)(6,6a,7,8,9,10-六氢-4H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉)的制备
Figure PCTCN2022075094-appb-000072
参照文献(Krogsgaard-Larsen等，J.Med.Chem.2014,57,5823-5828)方法进行制备。棕色固体。 1H NMR(800MHz,氘代氯仿)δ7.82(s,1H),7.08(t,J＝7.8Hz,1H),6.81(d,J＝8.1Hz,1H),6.73(t,J＝1.9Hz,1H),6.34(d,J＝7.6Hz,1H),3.81(d,J＝11.5Hz,1H),3.21(dd,J＝12.4,3.2Hz,2H),3.10–3.03(m,2H),2.97(dd,J＝15.2,3.7Hz,1H),2.83–2.79(m,3H).
实施例1：7-(4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丁氧基)-3,4-二氢喹啉-2(1H)-酮(化合物I-1)
Figure PCTCN2022075094-appb-000073
步骤1：往圆底烧瓶中依次加入7-羟基-3,4-二氢喹啉-2(1H)-酮(1.5g,9.19mmol),1,4-二溴丁烷(5.92g,27.6mmol)，K 2CO 3(1.9g,13.7mmol)和溶剂DMF(20mL)，反应体系在室温下搅拌过夜。减压蒸除溶剂，残余物用快速柱层析纯化(洗脱剂为含20-50％乙酸乙酯的乙酸乙酯/石油醚混合物)，得到中间体wha71(1.75g,64％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.74(s,1H),7.05(d,J＝8.3Hz,1H),6.52(dd,J＝8.3,1.9Hz,1H),6.30(d,J＝2.3Hz,1H),3.97(t,J＝6.1Hz,2H),3.48(t,J＝6.6Hz,2H),2.90(t,J＝7.5Hz,2H),2.65–2.60(m,2H),2.09–2.03(m,2H),1.95-1.93(m,2H).HR-MS(ESI,m/z):C 13H 17BrNO 2 +[M+H] +,计算值：298.0437；实测值：298.0432和300.0412。
步骤2：圆底烧瓶中依次加入中间体A(50mg,0.23mmol)，中间体wha71(82mg,0.28mmol)和K 2CO 3(0.2g,1.38mmol)，然后加入溶剂THF(3mL)和DMSO(1mL)。反应体系在60℃下加热搅拌16小时。反应结束后，除去溶剂，并用快速硅胶柱层析纯化(洗脱剂为0-10％甲醇/二氯甲烷)得化合物I-1(90mg,91％)，灰白色固体。 1H NMR(800MHz,氘代二甲亚砜)δ10.51(s,1H),9.97(d,J＝7.1Hz,1H),7.03(d,J＝8.2Hz,1H),6.88(t,J＝7.7Hz,1H),6.78(s,1H),6.70(d,J＝8.1Hz,1H),6.48(dd,J＝8.2,2.5Hz,1H),6.43(d,J＝2.5Hz,1H),6.20(d,J＝7.5Hz,1H),3.96–3.86(m,2H),3.74-3.69(m,1H),3.09–3.00(m,2H),2.96–2.87(m,2H),2.76(t,J＝6.8Hz,2H),2.71–2.61(m,2H),2.40(t,J＝7.7Hz,4H),2.20–2.14(m,1H),2.03–1.88(m,1H),1.76–1.68(m,2H),1.65–1.60(m,2H)； 13C NMR(201MHz,氘代二甲亚砜)δ170.40,157.75,140.00,139.26,134.17,128.46,123.05,117.70,116.56,115.74,107.57,106.08,103.24,101.80,98.96,66.72,55.71,55.00,53.69,50.62,43.43,30.79,26.26,25.87,24.03,20.32.HR-MS(ES,m/z):C 26H 31N 4O 2 +[M+H] +,计算值：431.2442；实测值:431.2440。
实施例2：7-(4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丁氧基)喹啉-2(1H)-酮(化合物I-2)
Figure PCTCN2022075094-appb-000074
步骤1：仿照实施例1步骤1的方法，以“7-羟基-喹啉-2(1H)-酮”和1,4-二溴丁烷为原料进行烷基化反应，制备中间体wha70(1.06g,38％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.79(d,J＝9.4Hz,1H),7.48(d,J＝8.4Hz,1H),6.87–6.83(m,2H),6.60(d,J＝9.3Hz,1H),4.11(t,J＝6.0Hz,2H),3.51(t,J＝6.6Hz,2H),2.12–2.07(m,2H),2.04–1.97(m,2H).HR-MS(ESI,m/z):C 13H 15BrNO 2 +[M+H] +, 计算值：296.0281；实测值:296.0220。
步骤2：仿照实施例1步骤2的方法，将中间体wha70与原料(A)进行烷基化反应，得到化合物I-2(60mg,61％)，制备HPLC纯化:t R＝18.5min(20-80％MeOH/H 2O)，白色固体。 1H NMR(800MHz,氘代甲醇)δ7.91(d,J＝9.4Hz,1H),7.61(d,J＝8.7Hz,1H),7.03(t,J＝7.8Hz,1H),6.92(dd,J＝8.7,2.4Hz,1H),6.89–6.84(m,3H),6.47(d,J＝9.4Hz,1H),6.40(d,J＝7.5Hz,1H),4.19(t,J＝5.8Hz,3H),3.79(t,J＝10.0Hz,2H),3.41–3.33(m,4H),3.19(dd,J＝15.2,3.9Hz,1H),3.14–3.06(m,2H),2.90(dd,J＝15.0,9.5Hz,1H),2.09–2.05(m,2H),2.00–1.96(m,2H)； 13C NMR(201MHz,氘代二甲亚砜)δ162.35,160.31,140.68,140.08,139.97,134.18,129.32,123.06,118.61,117.70,116.57,113.46,110.81,106.06,103.25,98.97,98.73,67.01,55.65,54.95,53.67,50.59,43.41,26.25,25.76,20.25；HR-MS(ESI,m/z):C 26H 29N 4O 2 +[M+H] +,计算值：429.2285；实测值：429.2281。
化合物I-2手性拆分。
手性分析条件：手性柱大赛璐CHIRALCEL OD-H(ODH0CD-TC013)(大赛璐)，柱体积:0.46cm(直径)x 15cm(柱长)(5μm填料)；流动相：MeOH/二乙胺＝100/0.1(V/V/)；流速：1.0mL/min；波长：UV 214nm；温度：35℃；HPLC仪器：Shimadzu LC-20AD。peak1(前峰)t R＝5.805min；peak2(后峰)：t R＝7.548min。
手性制备条件：手性柱CHIRALCEL OD(大赛璐)，柱体积:5.0cm(直径)x 25cm(柱长)(10μm填料)；流动相：MeOH/二乙胺＝100/0.1(V/V/)；流速：30mL/min；波长：UV 214nm；温度：38℃。
拆分制备：消旋体化合物I-2(0.103g)。peak1(前峰)t R＝5.830min，得到0.048g，>98％ee；旋光值[α] D 25＝+50.33°(c＝0.1,MeOH),>98％ee(化合物为三氟乙酸盐)。peak2(后峰)t R＝7.60min，得到0.042g，>98％ee；旋光值[а] D 25＝-45.00°(c＝0.1,MeOH),>98％ee(化合物为三氟乙酸盐)。
实施例3：5-(4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡唑[4,3,2-de]喹啉-8-基)丁氧基)苯并[d]噻唑(化合物I-3)
Figure PCTCN2022075094-appb-000075
步骤1：仿照实施例1步骤1的方法，以“5-羟基-苯并[d]噻唑”和1,4-二溴丁烷为原料制备中间体wha72(1.23g,65％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ8.98(s,1H),7.80(d,J＝8.7Hz,1H),7.60(d,J＝2.4Hz,1H),7.09(dd,J＝8.7,2.4Hz,1H),4.10(t,J＝6.1Hz,2H),3.51(t,J＝6.6Hz,2H),2.13–2.09(m,2H),2.04–1.97(m,2H).HR-MS(ESI,m/z):C 11H 13BrNOS +[M+H] +,计算值：285.9896；实测值：285.9894和287.9875。
步骤2：仿照实施例1步骤2的方法，将中间体wha72与原料(A)进行烷基化反应，得到化合 物I-3(30mg,51％)，黄色固体。 1H NMR(800MHz,氘代甲醇)δ9.18(s,1H),7.90(d,J＝8.8Hz,1H),7.59(d,J＝2.4Hz,1H),7.16(dd,J＝8.8,2.4Hz,1H),6.96(t,J＝7.8Hz,1H),6.78(d,J＝8.1Hz,1H),6.73(d,J＝1.6Hz,1H),6.29(d,J＝7.5Hz,1H),4.15–4.08(m,2H),3.80(d,J＝12.0Hz,1H),3.15–3.10(m,2H),3.09–3.05(m,1H),2.95(dd,J＝15.2,3.6Hz,1H),2.86–2.83(m,1H),2.79–2.76(m,1H),2.53(t,J＝4.8Hz,2H),2.37–2.34(m,1H),2.12(t,J＝10.9Hz,1H),1.92–1.85(m,2H),1.83–1.77(m,2H). 13C NMR(201MHz,氘代氯仿)δ158.55,155.05,154.79,142.34,134.44,125.59,124.18,122.15,118.18,116.59,115.04,109.55,106.60,102.06,99.12,68.28,60.25,58.35,56.28,53.13,46.38,27.63,27.36,23.60.HR-MS(ESI,m/z):C 24H 27N 4OS +[M+H] +,计算值：419.1900；实测值:419.1901。
实施例4：5-(4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丁氧基)-2-甲基苯并[d]噁唑(化合物I-4)
Figure PCTCN2022075094-appb-000076
步骤1：仿照实施例1步骤1的方法，以“2-甲基-5-羟基-苯并[d]噻唑”和1,4-二溴丁烷为原料制备中间体whb35(0.15g,31％)，浅黄色固体。 1H NMR(800MHz,氘代氯仿)δ7.35(d,J＝8.8Hz,1H),7.14(d,J＝2.5Hz,1H),6.89(dd,J＝8.8,2.5Hz,1H),4.03(t,J＝6.1Hz,2H),3.50(t,J＝6.7Hz,2H),2.64(s,3H),2.12–2.06(m,2H),2.00–1.94(m,2H). 13C NMR(201MHz,氘代氯仿)δ164.83,156.41,145.75,142.33,113.34,110.45,103.63,68.18,67.83,33.58,29.64,28.06,14.75.HR-MS(ESI,m/z):C 12H 15BrNO 2 +[M+H] +,计算值：284.0281；实测值:284.0280和286.0281。
步骤2：仿照实施例1步骤2的方法，将中间体whb35与原料(A)进行烷基化反应，得到化合物I-4(41mg,43％)，灰白色固体。 1H NMR(600MHz,氘代氯仿)δ7.90(s,1H),7.33(d,J＝8.8Hz,1H),7.13(d,J＝1.3Hz,1H),7.07(t,J＝7.7Hz,1H),6.88(dd,J＝8.8,1.8Hz,1H),6.79(d,J＝8.1,1.2Hz,1H),6.71(t,J＝1.8Hz,1H),6.33(d,J＝7.6Hz,1H),4.03(t,J＝6.2Hz,2H),3.80(d,J＝12.1Hz,1H),3.23(t,J＝11.0Hz,1H),3.11(d,J＝3.8Hz,2H),3.01–2.93(m,2H),2.81(dd,J＝13.8,11.0Hz,1H),2.60(d,J＝1.2Hz,3H),2.52(t,J＝7.6Hz,2H),2.41–2.34(m,1H),2.14(t,J＝10.9Hz,1H),1.88–1.85(m,2H),1.82–1.74(m,2H). 13C NMR(201MHz,氘代氯仿)δ164.76,156.53,145.69,142.42,134.44,124.15,118.17,115.10,113.33,110.39,109.40,103.68,102.12,99.14,68.64,60.00,58.31,56.13,52.96,46.24,29.82,27.69,27.43,23.45,14.73.HR-MS(ESI,m/z):C 25H 29N 4O 2 +[M+H] +,计算值：417.2285；实测值：417.2289。
实施例5：6-(4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丁氧基)-3-甲基苯并[d]异噁唑(化合物I-5)
Figure PCTCN2022075094-appb-000077
步骤1：仿照实施例1步骤1的方法，以“3-甲基-6-羟基-苯并[d]异噁唑”和1,4-二溴丁烷为原料制备中间体whb37(0.16g,42％)，浅黄色固体。 1H NMR(800MHz,氘代氯仿)δ7.52(d,J＝8.6Hz,1H),7.00(d,J＝2.3Hz,1H),6.89(dd,J＝8.7,2.4Hz,1H),4.03(t,J＝6.1Hz,2H),3.50(t,J＝6.6Hz,2H),2.62(s,3H),2.11–2.07(m,2H),2.01–1.95(m,2H). 13C NMR(201MHz,氘代氯仿)δ162.98,157.05,151.85,135.32,119.44,112.62,96.17,67.79,33.52,29.57,28.00,14.58.HR-MS(ESI,m/z):C 12H 15BrNO 2 +[M+H] +,计算值：284.0281；实测值:284.0261和286.0241。
步骤2：仿照实施例1步骤2的方法，将中间体whb37与原料(A)进行烷基化反应，得到化合物I-5(58mg,60％)，灰白色固体。 1H NMR(600MHz,氘代氯仿)δ8.03(s,1H),7.49(d,J＝8.7Hz,1H),7.06(t,J＝7.8Hz,1H),7.00(d,J＝2.5Hz,1H),6.89(dd,J＝8.7,2.4Hz,1H),6.77(d,J＝8.1Hz,1H),6.69(s,1H),6.32(d,J＝7.6Hz,1H),4.02(t,J＝6.3Hz,2H),3.79(d,J＝12.0Hz,1H),3.21(t,J＝10.8Hz,1H),3.09–3.06(m,2H),2.98–2.90(m,2H),2.81(dd,J＝15.4,10.9Hz,1H),2.58(s,3H),2.52–2.46(m,2H),2.34(t,J＝11.7Hz,1H),2.11(t,J＝10.9Hz,1H),1.91–1.82(m,2H),1.79–1.73(m,2H). 13C NMR(201MHz,氘代氯仿)δ162.87,157.17,151.85,142.22,135.21,134.41,124.09,119.37,118.15,115.09,112.65,109.35,102.12,99.07,96.13,68.58,60.10,58.25,56.19,53.01,46.28,27.69,27.34,23.43,14.53.HR-MS(ESI,m/z):C 25H 29N 4O 2 +[M+H] +,计算值：417.2285；实测值:417.2290。
实施例6：8-(4-((2,3-二氢苯并呋喃-6-基)氧基)丁基)-6,6a,7,8,9,10-六氢-4H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉(化合物I-6)
Figure PCTCN2022075094-appb-000078
步骤1：仿照实施例1步骤1的方法，以“6-羟基-2,3-二氢苯并呋喃”和1,4-二溴丁烷为原料制备中间体whb53(0.29g,81％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.05(d,J＝7.9Hz,1H),6.39–6.35(m,2H),4.57(t,J＝8.6Hz,2H),3.95(t,J＝6.1Hz,2H),3.48(t,J＝6.7Hz,2H),3.13(t,J＝8.6Hz,2H),2.08–2.02(m,2H),1.95–1.89(m,2H). 13C NMR(201MHz,氘代氯仿)δ161.44,159.64,124.93,119.03,106.53,96.87,72.16,67.24,33.65,29.64,29.22,28.14。
步骤2：仿照实施例1步骤2的方法，将中间体wha53与原料(A)进行烷基化反应，得到化合 物I-6(30mg,32％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.82(s,1H),7.08(t,J＝7.8Hz,1H),7.06–7.01(m,1H),6.80(d,J＝8.1Hz,1H),6.73(s,1H),6.40–6.37(m,2H),6.33(d,J＝7.6Hz,1H),4.56(t,J＝8.6Hz,2H),3.96(t,J＝6.2Hz,2H),3.82–3.78(m,1H),3.23–3.16(m,1H),3.15–3.10(m,2H),3.11–3.06(m,2H),3.00–2.95(m,2H),2.82(dd,J＝15.3,10.8Hz,1H),2.51–2.46(m,2H),2.39–2.31(m,1H),2.14–2.07(m,1H),1.85–1.80(m,2H),1.79–1.71(m,2H). 13C NMR(201MHz,氘代氯仿)δ161.41,159.77,134.44,124.90,124.18,118.85,118.17,115.09,109.46,106.60,102.11,99.16,96.90,72.13,68.06,59.98,58.30,56.12,52.95,46.23,29.21,27.69,27.40,23.40.HR-MS(ESI，m/z):C 25H 30N 3O 2 +[M+H] +,计算值：404.2333；实测值：404.2330。
实施例7：7-(3-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丙氧基)-3,4-二氢喹啉-2(1H)-酮(化合物I-7)
Figure PCTCN2022075094-appb-000079
步骤1：仿照实施例1步骤1的方法，以“7-羟基-3,4-二氢喹啉-2(1H)-酮”和1,3-二溴丙烷为原料制备中间体whb71(2.85g,81％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ8.94(s,1H),7.05(d,J＝8.1Hz,1H),6.54(dd,J＝7.9,2.4Hz,1H),6.41(d,J＝2.4Hz,1H),4.07(t,J＝5.8Hz,2H),3.59(t,J＝6.4Hz,2H),2.90(t,J＝8.7Hz,2H),2.63(t,J＝8.7Hz,2H),2.31–2.28(m,2H).HR-MS(ESI，m/z):C 12H 15BrNO 2 +[M+H] +,实测值：284.0281，计算值:284.0273和286.0255。
步骤2：仿照实施例1步骤2的方法，将中间体whb71与原料(A)进行烷基化反应，得到化合物I-7(60mg,63％)，灰白色固体。 1H NMR(800MHz,氘代氯仿)δ7.95(s,1H),7.89(s,1H),7.08(t,J＝7.8Hz,1H),7.04(d,J＝8.3Hz,1H),6.80(d,J＝8.1Hz,1H),6.72(s,1H),6.54(dd,J＝8.3,2.4Hz,1H),6.34(d,J＝7.6Hz,1H),6.32(d,J＝2.4Hz,1H),4.02(t,J＝6.3Hz,2H),3.81(d,J＝11.8Hz,1H),3.22(t,J＝9.7Hz,1H),3.12–3.07(m,2H),3.02–2.93(m,2H),2.89(t,J＝7.5Hz,2H),2.83(dd,J＝15.2,11.0Hz,1H),2.39(t,J＝11.6Hz,1H),2.16(t,J＝10.56Hz,1H),2.05–2.01(m,2H),1.81-1.67(m,4H). 13C NMR(201MHz,氘代二甲亚砜)δ170.31,157.88,141.95,139.21,134.02,128.42,122.97,117.86,115.56,107.66,102.07,101.69,98.01,65.86,59.55,56.06,54.40,52.51,45.91,30.76,27.09,26.17,24.00.HR-MS(ESI，m/z):C 25H 29N 4O 2 +[M+H] +,计算值：417.2285；实测值:417.2284。
实施例8：7-(3-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丙氧基)喹啉-2(1H)-酮(化合物I-8)
Figure PCTCN2022075094-appb-000080
步骤1：仿照实施例1步骤1的方法，以“7-羟基-喹啉-2(1H)-酮”和1,3-二溴丙烷为原料制备中间体whb73(1.36g,39％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ12.45(s,1H),7.74(d,J＝9.3Hz,1H),7.46(d,J＝8.6Hz,1H),6.88(d,J＝2.3Hz,1H),6.82(dd,J＝8.0and 2.4Hz,1H),6.57(d,J＝9.4Hz,1H),4.21(t,J＝5.7Hz,2H),3.62(t,J＝6.5Hz,2H),2.37–2.34(m,2H).HR-MS(ESI，m/z):C 12H 13BrNO 2 +[M+H] +,计算值：282.0124；实测值：282.0128和284.0109。
步骤2：仿照实施例1步骤2的方法，将中间体whb73与原料(A)进行烷基化反应，得到化合物I-8(0.10g,51％)，白色固体。 1H NMR(600MHz,氘代甲醇)δ7.91(d,J＝9.4Hz,1H),7.62(d,J＝8.7Hz,1H),7.07–7.01(m,1H),6.94(dd,J＝8.7,2.4Hz,1H),6.91–6.85(m,3H),6.48(d,J＝9.4Hz,1H),6.42(d,J＝7.6Hz,1H),4.26(t,J＝5.7Hz,2H),3.88–3.82(m,2H),3.52–3.46(m,2H),3.42–3.38(dd,J＝12.6,3.5Hz,1H),3.24–3.08(m,3H),2.92(dd,J＝15.3,9.6Hz,1H),2.41–2.36(m,2H),2.07–2.03(m,1H),1.62(t,J＝7.4Hz,1H). 13C NMR(201MHz,氘代二甲亚砜)δ162.32,160.03,140.63,140.05,134.16,129.37,123.05,118.78,117.70,116.56,113.60,110.58,106.08,103.23,98.90,65.09,53.78,53.50,50.77,48.62,43.51,26.29,23.44.HR-MS(ESI，m/z):C 25H 27N 4O 2 +[M+H] +,计算值：415.2129；实测值：415.2129。
实施例9：8-(3-(苯并[d][1,3]二氧杂环戊烯-5-基氧基)丙基)-6,6a,7,8,9,10-六氢-4H-吡嗪[1,2-a]吡咯并[4,3,2-de]喹啉(化合物I-9)
Figure PCTCN2022075094-appb-000081
步骤1：仿照实施例1步骤1的方法，以芝麻酚(CAS#533-31-3)和1,3-二溴丙烷为原料，制备得到中间体whb74(1.67g,45％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ6.70(d,J＝8.5Hz,1H),6.49(d,J＝2.5Hz,1H),6.33(dd,J＝8.5,2.5Hz,1H),5.91(s,2H),4.02(t,J＝5.8Hz,2H),3.59(t,J＝6.4Hz,2H),2.29–2.26(m,2H)。
步骤2：仿照实施例1步骤2的方法，将中间体whb74和原料(A)进行烷基化反应，制备得到化合物I-9(20mg,22％)，灰白色固体。 1H NMR(600MHz,氘代氯仿)δ7.87(s,1H),7.07(t,J＝7.8Hz,1H),6.79(d,J＝8.1Hz,1H),6.72–6.67(m,2H),6.50(d,J＝2.4Hz,1H),6.37–6.30(m,2H),5.90(s,2H),3.97(t,J＝6.3Hz,2H),3.80(d,J＝11.9Hz,1H),3.21(t,J＝10.7Hz,1H),3.08–3.07(m,2H),3.02–2.89(m,2H),2.82(dd,J＝15.3,11.0Hz,1H),2.59(t,J＝7.4Hz,2H),2.37(t,J＝11.7Hz,1H),2.14(t,J＝10.8 Hz,1H),2.05–1.96(m,2H). 13C NMR(201MHz,氘代二甲亚砜)δ154.09,147.91,141.95,141.01,134.01,122.96,117.85,115.54,108.02,107.65,105.72,102.05,100.92,97.99,97.82,66.64,59.54,56.05,54.40,52.50,45.91,27.09,26.22.HR-MS(ESI，m/z):C 23H 26N 3O 3 +[M+H] +,计算值：392.1969；实测值：392.1970。
实施例10：3-(4-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)反式环己烷基)-1,1-二甲基脲(化合物I-10)
Figure PCTCN2022075094-appb-000082
步骤1:圆底烧瓶中加入2-(4-((叔丁氧基羰基)氨基)反式环己基)乙酸(2.0g,7.77mmol)，溶剂DMF(15mL)，然后依次加入Cs 2CO 3(7.6g,23.3mmol)和溴化苄BnBr(5.32g,11.7mmol)，室温下搅拌过夜。反应结束后过滤，滤液浓缩后残余物柱层析纯化(洗脱剂为含0-20％甲醇的二氯甲烷)，得到目标化合物whb52(2.36g，收率87％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.39–7.30(m,5H),5.11(s,2H),4.36(s,1H),3.36(s,1H),2.24(d,J＝6.7Hz,2H),2.00–1.96(m,2H),1.79–1.72(m,3H),1.43(s,9H),1.14–1.04(m,4H).HR-MS(ESI，m/z):C 20H 29NO 4Na +[M+Na] +,计算值：370.1989；实测值：370.1989(M+Na)。
步骤2：将上一步whb52(0.16g,0.46mmol)溶于二氯甲烷(3mL)，加入三氟乙酸(1.5mL)，室温下搅拌3小时。减压浓缩，残余物溶于THF(5mL),然后依次加入Et 3N(1mL)和二甲基氨基甲酰氯(54mg,0.5mmol)。反应体系在室温下搅拌过夜。反应结束后，除去溶剂，硅胶柱层析纯化(洗脱剂为含0-20％甲醇的二氯甲烷)，得到目标化合物whb54(0.78g,83％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.38–7.30(m,5H),5.11(s,2H),3.60–3.55(m,1H),2.88(s,6H),2.26(d,J＝6.7Hz,2H),2.04–1.99(m,2H),1.80–1.76(m,3H),1.17–1.09(m,4H). 13C NMR(151MHz,氘代氯仿)δ172.80,157.86,136.07,128.59,128.23,128.19,66.12,49.49,41.47,36.19,34.23,33.69,31.76.HR-MS(ESI，m/z):C 18H 27N 2O 3 +[M+H] +,计算值：319.2016；实测值：319.2201。
步骤3:将whb54(0.78g，2.45mmol)溶于THF(20mL),氩气(Ar)保护下降温至-10℃。然后加入DABAL-H(14.7mL,1M)。然后反应体系0℃下继续搅拌5小时。反应结束后，用饱和酒石酸钠钾溶液(5mL)淬灭。除去溶剂后，硅胶柱层析纯化(洗脱剂为含0-20％甲醇的二氯甲烷)得到whb59(0.50g,收率95％)，白色固体。 1H NMR(600MHz,氘代氯仿)δ4.27(d,J＝7.7Hz,1H),3.65(t,J＝6.7Hz,2H),3.59-3.52(m,1H),2.88(s,6H),2.00(d,J＝10.6Hz,2H),1.81–1.75(m,2H),1.49–1.46(m,2H),1.40-1.34(m,1H),1.15–1.01(m,4H).HR-MS(ESI，m/z):C 11H 23N 2O 2 +[M+H] +,计算值：215.1754；实测值:215.1983。
步骤4：将whb59(0.65g,3.04mmol)和CBr 4(1.5g,4.56mmol)溶于二氯甲烷(15mL)中， 冰水浴冷却搅拌。加入PPh 3(1.2g,4.56mmol)，然后移至室温搅拌4小时。减压蒸除溶剂，残余物硅胶柱层析纯化(流动相为含0-3％甲醇的二氯甲烷)，得whb60(0.25g,38％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ4.16–4.00(m,1H),3.61–3.57(m,1H),3.43(t,J＝7.0Hz,1H),2.88(s,6H),2.03(d,J＝10.0,Hz,2H),1.80–1.74(m,4H),1.47-1.43(m,1H),1.14–1.03(m,4H).HR-MS(ESI，m/z):C 11H 22BrN 2O +[M+H] +,计算值：277.0910；实测值:277.0924和279.0925。
步骤5：实验方法同实施例1步骤2，以whb60和原料(A)进行烷基化反应，制备得到化合物I-10(0.18g,95％)，灰白色固体。 1H NMR(800MHz，氘代氯仿)δ7.93(s,1H),7.07(t,J＝7.8Hz,1H),6.79(d,J＝8.1Hz,1H),6.72(t,J＝1.7Hz,1H),6.33(d,J＝7.6Hz,1H),4.12(d,J＝7.6Hz,1H),3.79(d,J＝11.7,2.7Hz,1H),3.61–3.56(m,1H),3.21(s,1H),3.07(d,J＝10.2Hz,2H),2.97(dd,J＝15.2,3.7Hz,1H),2.93(t,J＝11.8Hz,1H),2.88(s,6H),2.84–2.78(m,1H),2.43(t,J＝7.9Hz,2H),2.32(t,J＝10.9Hz,1H),2.09(t,J＝10.8Hz,1H),2.04–1.99(m,2H),1.81–1.75(m,2H),1.49–1.46(m,2H),1.29–1.24(m,1H),1.14–1.04(m,3H). 13C NMR(201MHz,氘代氯仿)δ157.97,142.19,134.40,123.92,118.14,115.13,109.19,102.14,98.90,65.92,60.19,56.70,56.18,53.11,49.93,46.26,40.99,36.22,35.70,34.05,33.80,32.14,27.70,15.34.HR-MS(ESI，m/z):C 24H 36N 5O +[M+H] +,计算值：410.2914,实测值:410.2914。
化合物I-10的手性拆分
手性分析条件：手性柱CHIRALPAK IG(大赛璐)，柱体积:0.46cm(直径)x 15cm(柱长)(5μm粒径填料)；流动相：甲醇/乙腈/二乙胺＝80/20/0.1(V/V/V)；流速：1.0mL/min；波长：UV 210nm；温度：25℃；HPLC仪器：Shimadzu LC-2010BJ。peak1(前峰)t R＝3.113min；peak2(后峰)：t R＝4.622min。
手性制备条件：手性柱CHIRALPAK IG(大赛璐)，柱体积:2.5cm(直径)x 25cm(柱长)(10μm粒径填料)；流动相：甲醇/乙腈/二乙胺＝80/20/0.1(V/V/V)；流速：1.0mL/min；波长：UV 210nm；温度：25℃；HPLC仪器：Shimadzu LC-2010BJ。peak1(前峰)t R＝3.113min；peak2(后峰)：t R＝4.622min。
手性拆分：消旋体化合物I-10(1.20g)，(-)-I-10为前峰(peak1)，t R＝3.057min，得到0.566g，>99％ee，旋光[α] D 25＝-56.67°(c＝0.1,CHCl 3)；(+)-I-10为后峰(peak2)，t R＝4.512min，得到0.599g，>99％ee，旋光[α] D 25＝+50.33°(c＝0.1,CHCl 3)。
合成pNs-(+)-I-10并确定其手性构型：
Figure PCTCN2022075094-appb-000083
步骤：将(+)-I-10(23mg，0.056mmol)溶于DMF(3mL)，然后依次加入叔丁醇钾(13mg，0.116mmol)和对硝基苯磺酰氯(14mg,0.063mmol)，反应液在室温下搅拌一小时。反应结束后，加入水，然后用二氯甲烷溶剂萃取三次，合并有机相并浓缩。浓缩得到的粗产物用快速硅胶柱层析纯化 (洗脱剂为0-10％甲醇/二氯甲烷)得到橙黄色固体pNs-(+)-I-10(20mg，产率60％)。 1H NMR(800MHz,CDCl 3)δ8.27–8.23(m,2H),8.05–8.01(m,2H),7.32(d,J＝8.2Hz,1H),7.22(t,J＝8.0Hz,1H),7.01(d,J＝1.9Hz,1H),6.50(d,J＝7.9Hz,1H),4.10(d,J＝7.6Hz,1H),3.71-3.68(m,1H),3.60-3.55(m,1H),3.16-3.12(m,1H),3.07-3.04(m,2H),2.90-2.88(m,7H),2.69-2.65(m,1H),2.44-2.40(m,2H),2.28-2.25(m,1H),2.11–1.96(m,3H),1.78-1.75(m,2H),1.47-1.42(m,2H),1.33–1.27(m,1H),1.13–1.03(m,4H).HR-MS(ESI,m/z):C 30H 39N 6O 5S +[M+H] +，计算值：595.2697；实测值：595.2663。旋光值[α] D 25＝+47.67°(c＝0.1,CDCl 3)。
如式pNs-(+)-I-10所示的化合物的单晶制备
通过挥发法培养单晶：称取10mg化合物pNs-(+)-I-10产物于1mL氯仿中，再加入10mL石油醚。将试管放置在室温下缓慢挥发结晶，即可。
检测方法 X-射线单晶衍射
经检测，式pNs-(+)-I-10所示的化合物的晶系属于三斜晶系，P1空间群，晶胞参数为
Figure PCTCN2022075094-appb-000084
Figure PCTCN2022075094-appb-000085
α＝90.15°，β＝99.368°，γ＝90.25°，晶胞内不对称单位数Z为2；其X-射线单晶衍射如图1所示。
由X-射线单晶衍射的表征结果可以确定化合物pNs-(+)-I-10的构型为
Figure PCTCN2022075094-appb-000086
从而可以推导出(+)-I-10化合物的构型为
Figure PCTCN2022075094-appb-000087
相应地，(-)-I-10化合物的构型为
Figure PCTCN2022075094-appb-000088
实施例11：N-(4-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)反式环己基)四氢吡咯-1-甲酰胺(化合物I-11)
Figure PCTCN2022075094-appb-000089
步骤1：以whb52为原料，仿照实施例10步骤2的方法，以“四氢吡咯-1-甲酰氯”替换“二甲基氨基甲酰氯”，可制备得到中间体whb77(0.54g,87％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.39–7.30(m,5H),5.11(s,2H),3.95(br,1H),3.61-3.56(m,1H),3.31–3.29(m,4H),2.25(d,J＝6.8Hz,2H),2.06–2.00(m,2H),1.91–1.87(m,4H),1.65-1.59(m,2H),1.17–1.07(m,4H)。
步骤2：仿照实施例10步骤3的方法，将whb77转化为whb81(0.36g,96％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ3.69(t,J＝6.7Hz,2H),3.63-3.59(m,1H),3.34–3.32(d,J＝6.4Hz,4H),2.06–2.01(m,2H),1.93–1.88(m,4H),1.82–1.77(m,2H),1.50–1.47(m,2H),1.40–1.36(m,1H),1.15–1.05(m,4H).HR-MS(ESI，m/z):C 13H 25N 2O 2 +[M+H] +,计算值：241.1911；实测值:241.1945.
步骤3：仿照实施例10步骤4的方法，将中间体whb81转化为whb87(0.34g，收率76％)，白色固体。 1H NMR(600MHz,氘代氯仿)δ3.99–3.93(m,1H),3.63–3.58(m,1H),3.44(t,J＝7.0Hz,2H),3.32–3.29(m,4H),2.08–2.01(m,2H),1.93–1.85(m,3H),1.83–1.73(m,4H),1.50–1.40(m,1H),1.17–1.02(m,4H).HR-MS(ESI，m/z):C 13H 24BrN 2O +[M+H] +,计算值：303.1067；实测值:303.1073and305.1080。
步骤4：仿照实施例10步骤5的方法，将whb87与原料(A)进行烷基化反应，得到目标化合物I-11(50mg,50％)，灰白色固体。 1H NMR(800MHz,氘代氯仿)δ7.97(d,J＝4.7Hz,1H),7.07(t,J＝7.8Hz,1H),6.79(d,J＝8.1Hz,1H),6.72(d,J＝1.8Hz,1H),6.33(d,J＝7.6Hz,1H),3.95(d,J＝7.8Hz,1H),3.79(d,J＝11.9Hz,1H),3.63–3.58(m,1H),3.32–3.29(m,4H),3.22(t,J＝10.24Hz,1H),3.10–3.06(m,2H),2.98(dd,J＝15.3,3.8Hz,1H),2.94(d,J＝11.9Hz,1H),2.82(dd,J＝15.3,10.9Hz,1H),2.44(t,J＝7.9Hz,2H),2.36–2.30(m,1H),2.10(t,J＝10.8Hz,1H),2.05–2.01(m,2H),1.92–1.85(m,3H),1.80–1.75(m,2H),1.51–1.44(m,2H),1.29–1.24(m,1H),1.13–1.05(m,4H). 13C NMR(201MHz,氘代氯仿)δ156.13,141.91,134.14,123.77,117.87,114.85,114.83,109.04,101.83,98.74,98.72,59.86,56.45,55.87,52.82,49.30,45.97,45.29,35.45,33.93,33.52,31.91,27.42,25.37.HR-MS(ESI，m/z):C 26H 38N 5O +[M+H] +,计算值：436.3071；实测值：436.3072.
实施例12：N-(4-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)反式环己基)哌啶-1-甲酰胺(化合物I-12)
Figure PCTCN2022075094-appb-000090
步骤1：仿照实施例10步骤2的方法，以“哌啶-1-甲酰氯”替换“二甲基氨基甲酰氯”，可制备得到中间体whb80，白色固体。 1H NMR(800MHz,氘代氯仿)δ4.28–4.17(m,1H),4.12(q,J＝7.1Hz,2H),3.62–3.56(m,1H),3.31–3.27(m,4H),2.19(d,J＝7.0Hz,2H),2.02(m,2H),1.80–1.77(m,2H),1.59–1.57(m,2H),1.56–1.53(m,4H),1.25(t,J＝7.1Hz,3H),1.15–1.08(m,4H).HR-MS(ESI，m/z):C 16H 29N 2O 3 +[M+H] +,计算值：297.2173；实测值:297.2373。
步骤2：仿照实施例11步骤3的方法，将whb80转化为whb86，白色固体。 1H NMR(800MHz,氘代氯仿)δ4.27(s,1H),3.69(t,J＝6.6Hz,2H),3.59(s,1H),3.31–3.27(m,4H),2.02(dd,J＝7.0,3.7Hz,2H),1.81–1.75(m,2H),1.59-1.53(m,6H),1.48(q,J＝6.7Hz,2H),1.40–1.36(m,1H),1.12–1.04(m,4H).HR-MS(ESI，m/z):C 14H 27N 2O 2 +[M+H] +,计算值：255.2067；实测值:255.2057。
步骤3：仿照实施例10步骤4的方法，将中间体whb86转化为whb89(收率80％)，白色固体。 1H NMR(600MHz,氘代氯仿)δ4.25(s,1H),3.59(s,1H),3.44(t,J＝7.0Hz,2H),3.32–3.27(m,4H),2.04–2.02(m,2H),1.78–1.75(m,4H),1.62–1.50(m,5H),1.48–1.43(m,1H),1.17–1.00(m,4H).HR-MS(ESI，m/z):C 14H 26BrN 2O +[M+H] +,计算值：317.1223；实测值：317.1260和319.1141。
步骤4：仿照实施例10步骤5的方法，将whb89与原料(A)进行烷基化反应，得到目标化合物I-12(62mg,98％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.91(s,1H),7.07(t,J＝7.8Hz,1H),6.80(d,J＝8.1Hz,1H),6.72(t,J＝1.8Hz,1H),6.33(d,J＝7.6Hz,1H),4.20(d,J＝7.5Hz,1H),3.79(d,J＝11.9Hz,1H),3.61–3.57(m,1H),3.29(t,J＝5.5Hz,4H),3.22(s,1H),3.07(d,J＝10.9Hz,2H),2.98(dd,J＝15.2,3.8Hz,1H),2.94(d,J＝12.0Hz,1H),2.82(dd,J＝15.3,11.0Hz,1H),2.44(t,J＝8.0Hz,2H),2.33(t,J＝11.6Hz,1H),2.09(t,J＝10.8Hz,1H),2.04–1.99(m,2H),1.79(d,J＝12.3Hz,2H),1.61–1.54(m,5H),1.49–1.46(m,2H),1.29–1.23(m,1H),1.14–1.03(m,4H). 13C NMR(201MHz,氘代氯仿)δ156.97,141.98,134.13,123.79,117.86,114.77,109.13,101.78,98.74,65.67,59.95,56.46,55.91,52.87,49.61,49.50,46.01,44.66,40.82,35.49,33.77,33.60,31.90,27.43,25.39,24.25.HR-MS(ESI，m/z)：C 27H 40N 5O +[M+H] +,计算值：450.3227；实测值：450.3227。
实施例13：N-(4-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)反式环己基)-1H-吲哚-2-甲酰胺(化合物I-13)
Figure PCTCN2022075094-appb-000091
步骤1：圆底烧瓶中加入将2-(4-氨基反式环己基)乙酸甲酯(0.19g,1.02mmol)溶于四氢呋喃(5mL)，然后加入HATU(0.505g,1.33mmol)，DIPEA(1mL)和1H-吲哚-2-羧酸(0.214g,1.33mmol)，反应体系在室温下搅拌过夜。减压蒸除溶剂，残余物硅胶柱层析纯化(洗脱剂为含40-50％乙酸乙酯的石油醚)，得中间体whb108(0.30g,90％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ9.41(d,J＝62.1Hz,1H),7.64(d,J＝8.0Hz,1H),7.43(d,J＝8.2Hz,1H),7.28(d,J＝8.3Hz,1H),7.13(t,J＝7.4Hz,1H),6.85(d,J＝4.9Hz,1H),6.16(d,J＝33.4Hz,1H),4.14(q,J＝7.1Hz,2H),3.98–3.93(m,1H),2.24(dd,J＝13.8,7.0Hz,2H),2.12(d,J＝13.4Hz,2H),1.86(d,J＝13.4Hz,2H),1.83–1.79(m,1H),1.31(q,J＝12.8Hz,2H),1.26(t,J＝7.2Hz,3H),1.21–1.17(q,J＝12.8Hz,2H).HR-MS(ESI，m/z):C 19H 25N 2O 3 +[M+H] +,计算值：329.1860；实测值：329.1795。
步骤2：仿照实施例10步骤3中所述方法，将中间体whb108还原得到中间体whb149(80mg,47％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ9.23(s,1H),7.64(d,J＝8.0Hz,1H),7.43(d,J＝8.3Hz,1H),7.28(t,J＝8.2Hz,1H),7.14(t,J＝7.8Hz,1H),6.82–6.79(m,1H),3.97–3.93(m,1H),3.72(t,J＝6.6Hz,2H),2.15–2.10(m,2H),1.89–1.83(m,2H),1.54–1.51(m,2H),1.49–1.43(m,1H),1.31–1.23(m,2H),1.18–1.13(m,2H).HR-MS(ESI，m/z):C 17H 23N 2O 2 +[M+H] +,计算值：287.1754；实测值：287.1752。
步骤3：仿照实施例10步骤4的方法，将醇类中间体whb149转化为溴代物whb150(0.11g,45％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ9.31(s,1H),7.64(d,J＝8.0Hz,1H),7.43(d,J＝8.4Hz,1H),7.31–7.27(m,1H),7.13(t,J＝7.12Hz,1H),6.84(d,J＝2.2Hz,1H),6.10(d,J＝8.2Hz,1H),3.97–3.91(m,1H),3.46(t,J＝7.0Hz,2H),2.13(d,J＝13.4Hz,2H),1.88–1.83(m,2H),1.81(q,J＝6.9Hz,2H),1.55–1.51(m,1H),1.33–1.29(m,2H),1.16–1.11(m,2H).HR-MS(ESI，m/z):C 17H 22BrN 2O +[M+H] +,计算值：349.0910；实测值：349.0901和351.0884。
步骤4：仿照实施例10步骤5的方法，将whb150与原料(A)进行烷基化反应，得化合物I-13(33mg,收率30％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ9.16(s,1H),7.83(s,1H),7.64(dd,J＝8.0,1.1Hz,1H),7.43(dd,J＝8.3,1.1Hz,1H),7.28(dd,J＝8.2,7.0Hz,1H),7.14(dd,J＝8.0,7.0Hz,1H),7.08(t,J＝7.8Hz,1H),6.82–6.79(m,2H),6.73(d,J＝1.9Hz,1H),6.34(d,J＝7.6Hz,1H),5.95(d,J＝ 8.2Hz,1H),3.97–3.93(m,1H),3.82–3.78(m,1H),3.21(s,1H),3.08(d,J＝10.8Hz,2H),2.98(dd,J＝15.2,3.8Hz,1H),2.94(t,J＝11.8Hz,1H),2.83(dd,J＝15.2,11.1Hz,1H),2.46(t,J＝7.9Hz,2H),2.35–2.30(m,1H),2.16–2.06(m,3H),1.87(d,J＝11.96Hz,2H),1.52–1.50(m,2H),1.36–1.32(m,1H),1.29–1.24(m,2H),1.20–1.14(m,2H). 13C NMR(201MHz,氘代二甲亚砜)δ160.22,141.98,136.35,134.02,132.02,127.10,123.11,122.97,121.39,119.61,117.86,115.54,112.26,107.69,102.46,102.05,98.00,59.62,56.07,55.75,52.55,48.21,45.92,34.90,33.46,32.35,31.74,27.12.HR-MS(ESI，m/z):C 30H 36N 5O +[M+H] +,计算值：482.2914；实测值：482.2918。
实施例14：N-(4-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)反式环己基)苯甲酰胺(化合物I-14)
Figure PCTCN2022075094-appb-000092
步骤1：以“2-(4-((叔丁氧羰基氨基反式环己基)乙酸乙酯”为原料，仿照实施例10步骤2的方法，以“苯甲酰氯”替换“二甲基氨基甲酰氯”，得到中间体whb104(0.20g,收率69％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.74(d,J＝7.6Hz,2H),7.49(t,J＝7.4Hz,1H),7.42(t,J＝7.5Hz,2H),5.95–5.91(br,1H),4.14(q,J＝7.1Hz,2H),3.96–3.91(m,1H),2.23(dd,J＝13.9,7.0Hz,2H),2.11(d,J＝12.2Hz,2H),1.85(d,J＝13.3Hz,2H),1.82–1.77(m,1H),1.30–1.23(m,5H),1.21–1.16(m,2H).HR-MS(ESI，m/z):C 17H 24NO 3 +[M+H] +,计算值：290.1751；实测值：290.1748和312.1526(M+23Na)。
步骤2：仿照实施例10步骤3中所述方法，将中间体whb104还原得到中间体whb156(0.11g,收率65％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.77–7.73(m,2H),7.51–7.46(m,1H),7.45–7.40(m,2H),5.89(d,J＝8.1Hz,1H),3.96–3.91(m,1H),3.71(t,J＝6.8Hz,2H),2.14–2.09(m,2H),1.87–1.83(m,2H),1.53–1.50(m,2H),1.47–1.42(m,1H),1.28–1.20(m,2H),1.18–1.11(m,2H).HR-MS(ESI，m/z)：C 15H 22NO 2 +[M+H] +,计算值：248.1645；实测值：248.1772。
步骤3：仿照实施例10步骤4的方法，将醇类中间体whb156转化为溴代物whb158(78mg,57％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.76–7.73(m,2H),7.51–7.47(m,1H),7.43(dd,J＝8.3,7.1Hz,2H),5.89(d,J＝8.1Hz,1H),3.97–3.90(m,1H),3.46(t,J＝7.0Hz,2H),2.13(d,J＝13.2Hz,2H),1.87–1.82(m,2H),1.81–1.79(m,2H),1.54–1.48(m,1H),1.27–1.22(m,2H),1.16–1.11(m,2H).HR-MS(ESI，m/z)：C 15H 21BrNO +[M+H] +,计算值：310.0801；实测值：310.0792和312.0772。
步骤4：仿照实施例10步骤5的方法，将whb158与原料(A)进行烷基化反应，得目标化合物 I-14(30mg,收率32％)，黄色固体。 1H NMR(800MHz,氘代氯仿)δ7.84(s,1H),7.76–7.73(m,2H),7.52–7.46(m,1H),7.43(dd,J＝8.3,7.1Hz,2H),7.08(t,J＝7.8Hz,1H),6.80(d,J＝8.1Hz,1H),6.73(d,J＝1.9Hz,1H),6.34(d,J＝7.5Hz,1H),5.89(d,J＝8.1Hz,1H),3.97–3.92(m,1H),3.81(d,J＝11.7Hz,1H),3.25–3.21(m,1H),3.08(d,J＝10.9Hz,2H),2.99–2.93(m,2H),2.83(dd,J＝15.3,11.0Hz,1H),2.48–2.44(s,2H),2.36–2.32(m,1H),2.12(dd,J＝12.1,3.8Hz,3H),1.85(d,J＝12.8Hz,2H),1.53–1.50(m,2H),1.37–1.30(m,1H),1.26–1.13(m,4H). 13C NMR(201MHz,氘代二甲亚砜)δ165.87,142.44,135.36,134.48,131.38,128.59,127.71,123.43,118.32,116.02,108.13,102.53,98.47,56.51,56.20,53.01,49.04,46.36,40.91,35.37,33.88,32.65,32.23,27.58.HR-MS(ESI，m/z):C 28H 35N 4O +[M+H] +,计算值：443.2805；实测值：443.2807。
实施例15：N-(4-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)环己基)苯基磺酰胺(化合物I-15)
Figure PCTCN2022075094-appb-000093
步骤1：以“2-(4-((叔丁氧羰基氨基反式环己基)乙酸乙酯”为原料，仿照实施例10步骤2的方法，以“苯磺酰氯”替换“二甲基氨基甲酰氯”，得到中间体whb105(0.30g,收率89％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.88(d,J＝7.7Hz,2H),7.57(t,J＝7.4Hz,1H),7.51(t,J＝7.6Hz,2H),4.51(br,1H),4.09(q,J＝7.1Hz,2H),3.1–3.07(m,1H),2.14(dd,J＝14.4,6.9Hz,2H),1.83(d,J＝13.3Hz,2H),1.72(d,J＝13.6Hz,2H),1.69–1.65(m,1H),1.23(t,J＝7.1Hz,3H),1.20–1.15(m,2H),1.00–0.96(m,2H).HR-MS(ESI，m/z):[C 16H 23NO 4S+Na] +[M+Na] +,计算值：348.1240；实测值：348.1245。
步骤2：仿照实施例10步骤3中所述方法，将中间体whb105还原得到中间体whb155(0.22g,87％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.90–7.86(m,2H),7.59–7.55(m,1H),7.51(dd,J＝8.4,7.1Hz,2H),4.34(s,NH,1H),3.64(t,J＝6.6Hz,2H),3.11–3.06(m,1H),1.86–1.82(m,2H),1.72(d,J＝13.2Hz,2H),1.42(q,J＝6.7Hz,2H),1.36–1.28(m,1H),1.16–1.11(m,2H),0.96–0.90(m,2H).HR-MS(ESI，m/z):C 14H 22NO 3S +[M+H] +,计算值：284.1315；实测值：284.1332。
步骤3：仿照实施例10步骤4的方法，将醇类中间体whb155转化为溴代物whb159(0.10g,37％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ7.90–7.86(m,2H),7.59–7.55(m,1H),7.53–7.49(m,2H),4.38(br,1H),3.38(t,J＝7.0Hz,2H),3.12–3.07(m,1H),1.88–1.82(m,2H),1.74–1.68(m,4H),1.43–1.35(m,1H),1.19–1.12(m,2H),0.96–0.86(m,2H).HR-MS(ESI，m/z):C 14H 21BrNO 2S +[M+H] +,计算值：346.0471；实测值：346.0457和348.0435。
步骤4：仿照实施例10步骤5的方法，将whb159与原料(A)进行烷基化反应，得目标化合物I-15(40mg,98％)，淡黄色固体。 1H NMR(800MHz,氘代氯仿)δ7.90–7.86(m,2H),7.83(s,1H),7.59–7.55(m,1H),7.51(dd,J＝8.3,7.1Hz,2H),7.07(t,J＝7.8Hz,1H),6.80(d,J＝8.1Hz,1H),6.72(s,1H),6.32(d,J＝7.6Hz,1H),4.28(d,J＝7.6Hz,1H),3.80–3.77(s,1H),3.23–3.16(m,1H),3.12–3.08(m,1H),3.06–3.01(m,2H),2.97(d,J＝15.0Hz,1H),2.80(dd,J＝15.3,10.6Hz,1H),2.43-2.36(s,2H),2.31(s,1H),2.08-2.04(s,1H),1.84(d,J＝12.8Hz,3H),1.73(d,J＝13.4Hz,2H),1.45-1.39(m,2H),1.23-1.19(m,1H),1.17–1.09(m,2H),0.99–0.92(m,2H). 13C NMR(201MHz,氘代氯仿)δ142.12,141.61,141.59,134.37,132.46,129.10,126.89,123.98,118.12,115.15,109.17,102.19,99.00,60.04,56.50,56.09,53.20,52.98,46.17,40.89,35.08,33.88,33.48,31.90,27.65.HR-MS(ESI,m/z)：C 27H 35N 4O 2S +[M+H] +,计算值：479.2475；实测值：479.2487。
实施例16：3-(4-((4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)甲基)反式环己基)-1,1-二甲基脲(化合物I-16)
Figure PCTCN2022075094-appb-000094
步骤1：(4-(羟甲基)反式环己基)氨基甲酸叔丁酯(0.23g,1mmol)溶于DMF(5mL)中,然后依次加入三乙胺(1mL)和4-硝基苯磺酰氯(0.27g,1.2mmol)，反应体系在室温下搅拌过夜。反应结束后，减压浓缩，残余物硅胶柱层析纯化(洗脱剂为含0-10％甲醇的二氯甲烷)，得到中间体whb132(0.12g,29％)，白色固体。 1H NMR(800MHz,氘代氯仿)δ8.43–8.38(m,2H),8.12–8.08(m,2H),3.93(d,J＝6.5Hz,2H),3.42–3.29(m,1H),2.06–2.00(m,2H),1.78-1.76(m,2H),1.70–1.65(m,1H),1.43(s,9H),1.17–1.07(m,4H).HR-MS(ESI,m/z):C 18H 26N 2O 7SNa +[M+Na] +,计算值：437.1358；实测值:437.1323。
步骤2：将中间体whb132(0.12g,0.29mmol)溶于二氯甲烷(3mL)中,加入三氟乙酸(1.5mL)，室温下搅拌3小时。反应结束后，减压浓缩，残余物溶于四氢呋喃(5mL)，然后加入三乙胺(2mL)和二甲氨基甲酰氯(37mg,0.35mmol)，反应体系在室温下搅拌过夜。反应结束后，减压浓缩，残余物硅胶柱层析纯化(洗脱剂为含10-20％甲醇的二氯甲烷)，得到中间体whb133(30mg,27％)，白色固体。 1H NMR(800MHz,氘代二甲亚砜)δ8.48–8.43(m,2H),8.21–8.17(m,2H),5.86(d,J＝7.8Hz,1H),3.98(d,J＝6.4Hz,2H),3.29–3.25(m,1H),2.73(s,6H),1.76–1.71(m,2H),1.66–1.60(m,2H),1.57–1.51(m,1H),1.17–1.12(m,2H),0.97–0.92(m,2H)。HR-MS(ESI，m/z)：C 16H 24N 3O 6S +[M+H] +，计算值：386.1380；实测值：386.1391。
步骤3：圆底烧瓶中加入原料(A)(50mg,0.23mmol)，中间体whb133(30mg,0.078mmol)和K 2CO 3(127mg,0.92mmol),然后加入溶剂四氢呋喃(3mL)和二甲亚砜(1mL)。反应体系在60℃加热搅拌16小时。反应结束后，减压浓缩，残余物硅胶柱层析纯化(洗脱剂为含0-10％甲醇的二氯甲烷)，得到化合物I-16(12mg,13％)，灰白色固体。 1H NMR(800MHz,氘代氯仿)δ7.92(s,1H),7.06(t,J＝7.8Hz,1H),6.79(d,J＝8.1Hz,1H),6.71(d,J＝1.8Hz,1H),6.32(d,J＝7.6Hz,1H),4.14(d,J＝7.6Hz,1H),3.76(d,J＝11.8Hz,1H),3.63–3.58(m,1H),3.26–3.21(m,1H),3.03–2.94(m,3H),2.88(s,6H),2.80(dd,J＝15.3,10.9Hz,1H),2.34–2.30(m,1H),2.24–2.21(m,2H),2.11–2.07(m,1H),2.07–2.03(m,2H),1.91–1.85(m,2H),1.55–1.50(m,1H),1.14–1.02(m,4H)。 13C NMR(201MHz,氘代氯仿)δ157.94,142.25,134.37,123.81,118.13,115.09,109.13,102.07,98.78,65.01,60.65,56.13,53.38,50.10,46.23,40.93,36.19,34.49,33.83,30.61,27.62.HR-MS(ESI，m/z):C 23H 34N 5O +[M+H] +,计算值：396.2758；实测值：396.2755。
实施例17：3-(2-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)-2-甲基-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-4-酮(化合物I-17)
Figure PCTCN2022075094-appb-000095
仿照实施例1步骤2的方法，将原料(A)与“3-(2-氯乙基)-2-甲基-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-4-酮”(cas#63234-80-0,商业购买)进行烷基化反应，制备得到化合物I-17，墨绿色固体。进一步用制备HPLC纯化(流动相为20-80％MeOH/H 2O)，t R＝16min，得10mg(产率10％)。 1H NMR(800MHz,氘代二甲亚砜)δ10.68(s,1H),10.03(s,1H),6.97–6.92(m,1H),6.90(s,1H),6.80(d,J＝8.1Hz,1H),6.33(d,J＝7.5Hz,1H),4.11–4.05(m,1H),3.90–3.82(m,2H),3.80(t,J＝6.2Hz,2H),3.23–3.15(m,2H),3.08(d,J＝15.4Hz,2H),3.00–2.95(m,1H),2.93–2.84(m,2H),2.79(t,J＝6.7Hz,2H),2.75(dd,J＝15.4,9.2Hz,1H),2.26(s,3H),2.03–1.96(m,1H),1.88–1.85(m,2H),1.79–1.75(m,2H),1.48–1.43(m,1H). 13C NMR(201MHz,氘代二甲亚砜)δ161.57,158.89,157.56,139.89,134.14,123.03,117.65,116.57,114.91,105.99,103.20,98.97,54.84,53.65,50.49,43.45,42.42,30.65,26.26,21.14,21.12,20.79,20.76,18.35.HR-MS(ESI，m/z)：C 24H 30N 5O +[M+H] +,计算值：404.2445；实测值：404.2444。
实施例18：7-(4-(4-甲基-4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)丁氧基)喹啉-2(1H)-酮(化合物I-18)
Figure PCTCN2022075094-appb-000096
步骤1：圆底烧瓶中加入原料(A)(0.20g,0.94mmol)，三乙胺(0.4g,3.76mmol)，DMAP(12mg,0.094mmol)及溶剂DMF(5mL)，然后加入Boc 2O(0.23g,1.03mmol)，室温下搅拌12小时。反应结束后，减压浓缩除去溶剂，残余物硅胶柱层析纯化(洗脱剂是含0-10％甲醇的二氯甲烷)，得到中间体whb163(0.22g,75％)，灰白色固体。 1H NMR(800MHz,氘代氯仿)δ7.85(s,1H),7.09(t,J＝7.8Hz,1H),6.82(d,J＝8.0Hz,1H),6.75(d,J＝1.9Hz,1H),6.35(d,J＝7.6Hz,1H),4.31–4.21(m,1H),4.20–4.08(m,1H),3.81(d,J＝11.9Hz,1H),3.19–3.11(m,1H),3.11–3.01(m,2H),2.94–2.72(m,3H),1.49(s,9H)。HR-MS(ESI，m/z)：C 18H 24N 3O 2 +[M+H] +,计算值：314.1863；实测值：314.1862。
步骤2：圆底烧瓶中加入中间体whb163(0.21g,0.67mmol)和叔丁醇钾(0.091g,0.81mmol)及DMF(8mL)，搅拌30分钟。加入碘甲烷(0.19g,1.34mmol)，继续在室温下搅拌3小时。反应结束后，往反应体系中加入水(3mL)淬灭反应，有固体析出，过滤得到中间体whb165粗品(0.18g,82％)，黄色固体，直接用于下一步。 1H NMR(800MHz,氘代氯仿)δ7.13–7.08(m,1H),6.75(d,J＝8.1Hz,1H),6.59(s,1H),6.33(d,J＝7.6Hz,1H),4.29–4.24(m,1H),4.21–4.08(m,2H),3.82–3.80(m,1H),3.73(s,3H),3.17–3.10(m,1H),3.09–3.04(m,1H),3.01(d,J＝15.2Hz,1H),2.80(t,J＝13.0Hz,2H),1.48(s,9H)。HR-MS(ESI，m/z):C 19H 26N 3O 2 +[M+H] +,计算值：328.2020；实测值：328.1990。
步骤3:将中间体whb165(50mg)溶于二氯甲烷(3mL)中，加入TFA(1mL)，室温下搅拌1小时。减压蒸除溶剂得粗品，直接用于下一步。
步骤4：步骤3中所得粗产物溶于四氢呋喃THF(3mL)，然后加入DMSO(1.5mL)，K 2CO 3(0.12g,0.87mmol)和实施例2中所述中间体wha70(49mg,0.17mmol)，60℃下加热搅拌16小时。减压蒸除溶剂，残余物硅胶柱层析纯化(洗脱剂为含0-10％甲醇的二氯甲烷)，得到目标化合物I-18(30mg,45％)，淡黄色固体。 1H NMR(800MHz,氘代甲醇)δ7.89(d,J＝9.4Hz,1H),7.59(d,J＝8.7Hz,1H),7.03(t,J＝7.8Hz,1H),6.91(dd,J＝8.7,2.4Hz,1H),6.87(d,J＝2.4Hz,1H),6.78(d,J＝8.2Hz,1H),6.67(s,1H),6.45(d,J＝9.4Hz,1H),6.34(d,J＝7.5Hz,1H),4.18–4.14(m,2H),3.85(d,J＝12.0Hz,1H),3.74(s,3H),3.21–3.16(s,2H),3.11–3.05(m,1H),2.96(d,J＝15.3Hz,1H),2.87(t,J＝12.0Hz,1H),2.80–2.76(m,1H),2.63–2.57(m,2H),2.46–2.40(m,1H),2.23–2.16(m,1H),1.94–1.90(m,2H),1.86–1.81(m,2H). 13C NMR(201MHz，氘代氯仿)δ165.14,161.51,142.23,141.00,140.50,135.48,129.14, 123.76,119.86,118.39,117.98,114.32,112.78,108.19,100.42,99.15,98.64,68.23,60.01,58.27,56.31,53.00,46.31,32.96,27.67,27.28,23.39.HR-MS(ESI，m/z):C 27H 31N 4O 2 +[M+H] +,计算值：443.2442；实测值：443.2445。
实施例19：1,1-二甲基-3-(4-(2-(4-甲基-4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)乙基)反式环己基)脲(化合物I-19)
Figure PCTCN2022075094-appb-000097
采用与实施例17相似的方法，以whb165先脱除Boc保护基，再与中间体whb60进行烷基化反应，得目标化合物I-19(50mg,79％)，淡黄色固体。进一步用HPLC纯化(流动相为20-80％MeOH/H 2O)，t R＝19.5min，得40mg。 1H NMR(800MHz,氘代甲醇)δ7.08–7.04(m,1H),6.83(d,J＝8.2Hz,1H),6.75(s,1H),6.39(d,J＝7.6Hz,1H),4.15(d,J＝14.1Hz,1H),3.73(s,3H),3.73–3.68(m,2H),3.51–3.47(m,1H),3.37–3.32(m,1H),3.26–3.20(m,3H),3.15–3.12(m,1H),3.05(t,J＝13.32Hz,1H),3.00(t,J＝11.9Hz,1H),2.87(s,6H),2.87–2.81(m,1H),1.95–1.89(m,2H),1.85–1.84(m,2H),1.74–1.65(m,2H),1.39–1.32(m,1H),1.32–1.26(m,2H),1.16–1.10(m,2H). 13C NMR(201MHz,氘代甲醇)δ159.12,139.54,135.63,123.24,120.54,118.09,105.75,101.38,99.12,55.68,55.45,54.33,50.96,49.78,43.76,35.04,34.70,32.64,31.54,31.52,30.33,26.24.HR-MS(ESI，m/z):C 25H 38N 5O +[M+H] +,计算值：424.3071；实测值：424.3089。
实施例20：(E)-7-((4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-2-丁烯-1-基)氧基)-3,4-二氢喹啉-2(1H)-酮(化合物I-20)
Figure PCTCN2022075094-appb-000098
步骤1：仿照实施例1步骤1的方法，以7-羟基-3,4-二氢喹啉-2(1H)-酮和(E)-1,4-二溴-2-丁烯为原料进行烷基化反应，制备中间体whc102(0.82g,45％)，黄色固体。 1H NMR(800MHz,CDCl 3)δ8.45(s,1H),7.05(d,J＝8.2Hz,1H),6.57–6.49(m,1H),6.37(d,J＝2.5Hz,1H),6.07(dt,J＝15.2,7.4Hz,1H),5.97(dt,J＝15.2,5.3Hz,1H),4.52(d,J＝5.4Hz,2H),3.99(d,J＝7.5Hz,2H),2.90(t,J＝7.5Hz,2H),2.62 (t,J＝7.5Hz,2H).HR-MS(ESI，m/z):C 13H 15BrNO 2 +[M+H] +,计算值：296.0281；实测值：296.0294和298.0277.
步骤2：仿照实施例1步骤2的方法，将中间体A与whc102进行烷基化反应，得到化合物I-20(40mg，33％)，淡黄色固体。HR-MS(ESI，m/z):C 26H 29N 4O 2 +[M+H] +,计算值：429.2285；实测值：429.2288.
实施例21：(E)-7-((4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-2-丁烯-1-基)氧基)喹啉-2(1H)-酮(化合物I-21)
Figure PCTCN2022075094-appb-000099
步骤1：仿照实施例1步骤1的方法，以7-羟基-喹啉-2(1H)-酮和(E)-1,4-二溴-2-丁烯为原料进行烷基化反应，制备中间体whc72(0.25g,14％)，黄色固体。 1H NMR(600MHz,CDCl 3)δ7.74(d,J＝9.4Hz,1H),7.46(d,J＝8.7Hz,1H),6.88(d,J＝2.4Hz,1H),6.86–6.80(m,1H),6.59–6.47(m,1H),6.14(dt,J＝15.0,7.4Hz,1H),6.01(dt,J＝15.4,5.5Hz,1H),4.66(d,J＝5.3Hz,2H),4.01(d,J＝7.5Hz,2H).HR-MS(ESI，m/z):C 13H 13BrNO 2 +[M+H] +,计算值：294.0124；实测值：294.0124和296.0106.
步骤2：仿照实施例1步骤2的方法，将中间体A与whc72进行烷基化反应，得到化合物I-21(50mg，51％)，灰白色固体。 1H NMR(800MHz,CDCl 3)δ10.12(s,1H),7.83(s,1H),7.69(d,J＝9.4Hz,1H),7.45(d,J＝8.7Hz,1H),7.07(t,J＝7.8Hz,1H),6.85–6.82(m,1H),6.80(d,J＝8.1Hz,1H),6.72(d,J＝2.0Hz,1H),6.69(s,1H),6.51(d,J＝9.4Hz,1H),6.32(d,J＝7.6Hz,1H),6.03–5.98(m,1H),5.95–5.91(m,1H),4.65(d,J＝5.6Hz,2H),4.14–4.10(m,1H),3.80(d,J＝11.7Hz,1H),3.22–3.20(m,1H),3.14(t,J＝8.7Hz,1H),3.07(t,J＝14.4Hz,2H),2.94(dd,J＝15.1,3.7Hz,2H),2.83–2.77(m,1H),2.40–2.36(m,1H),2.12(t,J＝10.8Hz,1H).HR-MS(ESI，m/z):C 26H 27N 4O 2 +[M+H] +,计算值：427.2129；实测值：427.2129.
实施例22：(E)-7-((4-(4-甲基-4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-2-丁烯-1-基)氧基)-3,4-二氢喹啉-2(1H)-酮(化合物I-22)
Figure PCTCN2022075094-appb-000100
仿照实施例18步骤3的方法，将中间体whb165脱除Boc保护基，再与中间体whc102进行烷基化反应，得目标化合物I-22(90mg，30％)，棕色泡沫状固体。 1H NMR(800MHz,MeOD)δ7.09–7.04 (m,2H),6.82(d,J＝8.2Hz,1H),6.72(s,1H),6.58(dd,J＝8.3,2.5Hz,1H),6.49(d,J＝2.5Hz,1H),6.36(d,J＝7.5Hz,1H),6.26–6.22(m,1H),5.97–5.93(m,1H),4.66–4.62(m,2H),4.11–4.05(m,1H),3.84–3.75(m,2H),3.71(s,3H),3.64–3.59(m,1H),3.56–3.52(m,1H),3.13–3.09(m,1H),3.08–3.00(m,2H),2.82(t,J＝8.0Hz,3H),2.77(dd,J＝15.6,8.0Hz,1H),2.48(t,J＝8.0Hz,2H).HR-MS(ESI，m/z):C 27H 31N 4O 2 +[M+H] +,计算值：443.2442；实测值：443.2442.
实施例23：(E)-7-((4-(4-甲基-4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-2-丁烯-1-基)氧基)喹啉-2(1H)-酮(化合物I-23)
Figure PCTCN2022075094-appb-000101
仿照实施例18步骤3的方法，将中间体whb165脱除Boc保护基，再与中间体whc72进行烷基化反应，得目标化合物I-23(23mg，20％)，棕黄色固体。 1H NMR(800MHz,DMSO)δ11.60(s,1H),7.80(d,J＝9.5Hz,1H),7.56(d,J＝8.3Hz,1H),6.94(t,J＝7.8Hz,1H),6.84–6.80(m,2H),6.76–6.71(m,2H),6.31(d,J＝9.4Hz,1H),6.22(d,J＝7.5Hz,1H),5.94–5.90(m,2H),4.63(d,J＝5.1Hz,2H),3.72–3.69(m,1H),3.68(s,3H),3.06–3.02(m,2H),2.98–2.94(m,3H),2.82(d,J＝15.2Hz,1H),2.69–2.65(m,1H),2.63–2.57(m,1H),2.21–2.17(m,1H),1.97–1.93(m,1H).HR-MS(ESI，m/z):C 27H 29N 4O 2 +[M+H] +,计算值：441.2285；实测值：441.2286.
实施例24：1-(4-氟苯)-4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-1-丁酮(化合物I-24)
Figure PCTCN2022075094-appb-000102
步骤1：圆底烧瓶中加入环丙烷基(4-氟苯)甲酮(0.5g，3mmol)和氢溴酸水溶液(3mL)，反应体系在80℃下搅拌2小时。反应结束后，冷却，加水，加DCM萃取三次。合并有机相，减压浓缩，得到粗产物whc48(0.73g，98％)黄色液体。 1H NMR(800MHz,CDCl 3)δ8.04–7.99(m,2H),7.17–7.12(m,2H),3.55(t,J＝6.3Hz,2H),3.16(t,J＝6.9Hz,2H),2.31(p,J＝6.6Hz,2H).
步骤2：仿照实施例1步骤2的方法，将中间体A与whc48进行烷基化反应，得到化合物I-24(0.3g，57％)，淡黄色固体。 1H NMR(800MHz,CDCl 3)δ8.03–7.98(m,2H),7.81(s,1H),6.80(d,J＝8.1Hz,1H),6.72(d,J＝1.9Hz,1H),6.32(d,J＝7.6Hz,1H),3.77(d,J＝11.7Hz,1H),3.16–3.12(m,1H),3.05–3.01(m,4H),2.96(dd,J＝15.2,3.7Hz,1H),2.88–2.78(m,2H),2.49(t,J＝7.1Hz,2H),2.35(t,J＝8.0Hz,1H),2.11(t,J＝8.0Hz,1H),2.03–2.00(m,2H).HR-MS(ESI，m/z):C 23H 25FN 3O +[M+H] +,计算 值：378.1976；实测值：378.1976。
实施例25：1-(4-氟苯)-4-(4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-1-丁醇(化合物I-25)
Figure PCTCN2022075094-appb-000103
将I-24(50mg，0.13mmol)溶于甲醇(5mL)，然后加入NaBH 4(7.6mg，0.19mmol)，反应体系在室温下搅拌2小时。反应结束后，加水淬灭反应并减压浓缩，残余物用快速硅胶柱层析纯化(洗脱剂为含20-30％甲醇的二氯甲烷)，得到I-25(30mg,61％)，灰白色固体。 1H NMR(600MHz,CDCl 3)δ7.82(s,1H),7.36–7.30(m,2H),7.10–7.04(m,1H),7.01–6.97(m,2H),6.81(d,J＝8.1,1.3Hz,1H),6.73(d,J＝7.7Hz,1H),6.34(dd,J＝7.6,2.4Hz,1H),4.69(td,J＝8.2,2.8Hz,1H),3.87–3.80(m,1H),3.34–3.30(m,1H),3.23–3.19(m,1H),3.08–2.91(m,3H),2.83–2.79(m,1H),2.54–2.50(m,2H),2.48–2.37(m,1H),2.25–2.14(m,1H),2.00–1.96(m,1H),1.88–1.84(m,1H),1.76–1.72(m,2H).HR-MS(ESI，m/z):C 23H 27FN 3O +[M+H] +,计算值：380.2133；实测值：380.2133。
实施例26：1-(4-氟苯)-4-(4-甲基-4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-1-丁酮(化合物I-26)
Figure PCTCN2022075094-appb-000104
仿照实施例18步骤3的方法，将中间体whb165脱除Boc保护基，再与中间体whc48进行烷基化反应，得目标化合物I-26(20mg,15％)，淡黄色固体。 1H NMR(800MHz,DMSO)δ8.04(dd,J＝8.6,5.5Hz,2H),7.32(t,J＝8.7Hz,2H),6.93(t,J＝7.8Hz,1H),6.75(s,1H),6.71(d,J＝8.1Hz,1H),6.20(d,J＝7.5Hz,1H),3.69–3.68(m,1H),3.67(s,3H),3.04–3.00(m,3H),2.99–2.95(m,1H),2.91–2.84(m,2H),2.63–2.60(m,1H),2.59–2.55(m,1H),2.42–2.38(m,2H),2.20–2.16(m,1H),2.00–1.95(m,1H),1.88–1.84(m,2H).HR-MS(ESI，m/z):C 24H 27FN 3O +[M+H] +,计算值：392.2133；实测值：393.2133。
实施例27：1-(4-氟苯)-4-(4-甲基-4,6,6a,7,9,10-六氢-8H-吡嗪[1,2-a]吡咯[4,3,2-de]喹啉-8-基)-1-丁醇(化合物I-27)
Figure PCTCN2022075094-appb-000105
将I-26(63mg，0.16mmol)溶于甲醇(8mL)，然后加入NaBH 4(9mg，0.24mmol)，反应体系在室温下搅拌2小时。反应结束后，加水淬灭反应并减压浓缩，残余物用快速硅胶柱层析纯化(洗脱剂为含20-30％甲醇的二氯甲烷)，得到I-27(10mg,16％)，淡黄色固体。 1H NMR(800MHz,CDCl 3)δ7.36–7.31(m,2H),7.09(t,J＝7.7Hz,1H),7.00–6.97(m,2H),6.73(d,J＝7.8Hz,1H),6.59–6.55(m,1H),6.31(d,J＝7.7Hz,1H),4.70–4.67(m,1H),3.86–3.79(m,1H),3.72(s,3H),3.33–3.29(m,1H),3.19–3.15(m,1H),3.05–2.92(m,3H),2.85–2.76(m,1H),2.52–2.48(m,2H),2.43–2.39(m,1H),2.19–2.15(m,1H),2.00–1.96(m,1H),1.87–1.83(m,1H),1.77–1.73(m,1H),1.72–1.68(m,1H).HR-MS(ESI，m/z):C 24H 29FN 3O +[M+H] +,计算值：394.2289；实测值：394.2297。
测试例1：本发明化合物对于多巴胺D2受体的亲和力测试
本发明化合物对于多巴胺D2受体的亲和力采用放射性配体竞争性实验的方法进行测定。第一步，制备含有特定多巴胺D 2受体的细胞膜组分。10cm培养皿以10ng多巴胺D 2受体和40μL PEI进行转染，48小时后，从细胞房拿出10厘米培养皿，其中培养的细胞已表达多巴胺D 2受体。用真空泵吸掉培液，每孔加入3mL裂解液，将细胞置于4℃冷库，静置10分钟。待细胞脱落后，将其转移到15mL离心管中，4℃离心机1500rpm离心5分钟，弃上清。将细胞沉淀转移到组织匀浆器中，再向其中加入3mL裂解液，充分研磨至细胞破碎。然后，将细胞悬液等分至多个EP管中，4℃离心机12000rpm离心5min，弃上清。沉淀即为含有多巴胺D2受体的细胞膜组分。第二步，对瞬时表达多巴胺D 2受体的293T膜组分进行配体受体结合实验。首先，向含有多巴胺D 2受体的细胞膜组分加入标准结合缓冲液，用电动组织匀浆器将细胞膜破碎重悬。96孔板每孔加入30μL膜蛋白悬液。然后，96孔板从左到右依次加入30μL不同药物，保证药物终浓度由下到上依次为10 -5M、10 -6M、10 -7M、10 -8M、10 -9M、0M，每种处理两个重复。紧接着，96孔板每孔加入30μL[ 3H]-Methylspiperone。室温避光孵育2小时。检测。机器读值反应膜上结合[ 3H]-Methylspiperone的量，进一步数据处理后得到不同化合物对多巴胺D2受体的亲和力K i值。
结果如表1所示。结果表明，化合物I-1到化合物I-27对多巴胺D 2受体均有一定的亲和活性，可见本发明的化合物对多巴胺D 2受体均有一定的亲和活性。
表1
化合物 亲和力Ki(pKi±SEM)
I-1 33.65nM(7.47±0.16)
I-2 9.03nM(8.04±0.12)
(+)-I-2 8.87nM(8.05±0.05)
(-)-I-2 1.75nM(8.76±0.13)
I-3 49.58nM(7.30±0.20)
I-4 30.34nM(7.52±0.08)
I-5 37.07nM(7.43±0.09)
I-6 51.56nM(7.29±0.10)
I-7 402.71nM(6.40±0.12)
I-8 0.49nM(9.31±0.15)
I-9 751.97nM(6.12±0.10)
I-10 50.64nM(7.30±0.08)
(-)-I-10 22.44nM(7.65±0.08)
(+)-I-10 1135.01nM(5.95±0.17)
I-11 22.23nM(7.65±0.06)
I-12 27.14nM(7.57±0.03)
I-13 16.31nM(7.79±0.07)
I-14 40.71nM(7.39±0.05)
I-15 77.45nM(7.11±0.12)
I-16 1992.20nM(5.70±0.14)
I-17 55.75nM(7.25±0.12)
I-18 60.95nM(7.22±0.02)
I-19 52.68nM(7.28±0.15)
I-20 70.9nM
I-21 33.2nM
I-22 176nM
I-23 100.5nM
I-24 32.4nM
I-25 10.8nM
I-26 1352nM
I-27 383.1nM
阿立哌唑 5.95nM(8.23±0.08)
备注：数据使用[ 3H]-Methylspiperone(0.3-0.5nM)作为放射性配体的竞争结合实验的平均K i(pK i±SEM)。其中，化合物I-1至19所有数据均为三次独立测定的mean±SEM(n＝3次独立实验)；化合物I-20至27采用单次测定的。
测试例2：化合物对于多巴胺D2受体的功能活性测试
为了检测多巴胺D 2受体介导的下游G蛋白信号通路，第一天，6厘米培养皿以1μg多巴胺D 2 受体、1μg含有C端海藻荧光素酶的Gα i1(Gα i1-Rluc)、1μg G β3、1μg含有C端绿色荧光蛋白的Gγ 9(Gγ 9-GFP)和16μL PEI进行转染。同时，为了检测多巴胺D 2受体介导的下游β-arrestin2信号通路，第一天，6厘米培养皿以500μg含有C端海藻荧光素酶的多巴胺D 2受体(D 2-Rluc)、500μg G蛋白偶联受体激酶2(GRK2)、2500μg含有N端绿色荧光蛋白的β-arrestin2(GFP2-ARRB2)和14μL PEI进行转染。第二天，消化长满的细胞，以一个长满细胞的6厘米培养皿细胞量铺一个96孔板，每孔100μL培液。第三天，加药检测。从细胞房中拿出96孔板去除培液，每孔加入40μL底物腔肠素400a(终浓度5μM)，紧接着从左到右依次加入20μL不同的药物，保证药物终浓度由下到上梯度递减，每种处理两个重复，最后，上机检测。机器读值反应胞内β-arrestin2上膜情况以及G蛋白三聚体解离情况，前者表征多巴胺D 2受体下游β-arrestin2信号通路激活程度后者表征多巴胺D 2受体下游G蛋白信号通路激活程度，由此，各种化合物对多巴胺D 2受体的激动作用可被揭示。结果如表2所示。
结果表明，化合物I-1到化合物I-25对多巴胺D 2受体均有一定的激动活性。
表2
Figure PCTCN2022075094-appb-000106
Figure PCTCN2022075094-appb-000107
备注：化合物I-1至19所有数据均为三次独立测定的mean±SEM(n＝3次独立实验)；化合物I-20至27采用单次测定的。 1EC 50是在实验中给出半数最大反应的化合物浓度。 2括号E max％表示化合物在实验中产生的最大反应强度(E max)相对于内源性配体多巴胺的百分比。
实施例3：本发明化合物对5-HT2A受体的亲和力测试
本发明化合物对于5-HT 2A受体的亲和力采用放射性配体竞争性实验的方法进行测定。第一步，制备含有特定5-HT 2A受体的细胞膜组分。10cm培养皿以10ng 5-HT 2A受体和40μL PEI进行转染，48小时后，从细胞房拿出10厘米培养皿，其中培养的细胞已表达5-HT 2A受体。用真空泵吸掉培液，每孔加入3mL裂解液，将细胞置于4℃冷库，静置10分钟。待细胞脱落后，将其转移到15mL离心管中，4℃离心机1500rpm离心5分钟，弃上清。将细胞沉淀转移到组织匀浆器中，再向其中加入3mL裂解液，充分研磨至细胞破碎。然后，将细胞悬液等分至多个EP管中，4℃离心机12000rpm离心5min，弃上清。沉淀即为含有5-HT 2A受体的细胞膜组分。第二步，对瞬时表达5-HT 2A受体的293T膜组分进行配体受体结合实验。首先，向含有5-HT 2A受体的细胞膜组分加入标准结合缓冲液，用电动组织匀浆器将细胞膜破碎重悬。96孔板每孔加入30μL膜蛋白悬液。然后，96孔板从左到右依次加入30μL不同药物，保证药物终浓度由下到上依次为10 -5M、10 -6M、10 -7M、10 -8M、10 - 9M、0M，每种处理两个重复。紧接着，96孔板每孔加入30μL[ 3H]-ketanserin。室温避光孵育2小时。检测。机器读值反应膜上结合[ 3H]-ketanserin的量，进一步数据处理后得到不同化合物对5-HT 2A受体的亲和力K i值。结果如表3所示。
表3
化合物 K i,nM(pK i±SEM)
I-1 3639.15(5.44±0.02)
I-2 906.78(6.04±0.01)
I-10 2371.37(5.63±0.04)
(-)-I-10 2627.24(5.58±0.09)
(+)-I-10 2480.28(5.61±0.09)
阿立哌唑 42.17(7.38±0.03)
表3结果表明，化合物I-1，I-2，I-10，(-)-I-10和(+)-I-10对5-HT 2A受体的亲和力很弱。对比表1的数据，化合物I-1，I-2，(-)-I-10对5-HT 2A受体的结合选择性大于100倍，可见本发明的化合物对多巴胺D 2受体具有很好的选择性。
测试例3：本发明化合物的小鼠药代动力学性质测试
1.化合物(-)-I-10经灌胃、腹腔注射和静脉注射单次给予C57雄性小鼠的药代动力学性质测试
(1)实验目的
化合物(-)-I-10在C57雄性小鼠体内单剂量给药后，于不同时间点采集血样，LC-MS/MS测定小鼠血浆中化合物的浓度并计算相关药代参数，考察化合物在小鼠体内药代动力学情况。
(2)实验设计
雄性C57小鼠27只，由苏州昭衍实验动物有限责任公司提供，按下表4进行实验。
表4
Figure PCTCN2022075094-appb-000108
(3)样品采集
每只动物每次通过眼眶取0.030mL血液，EDTA-K2抗凝，采集时间点为：给予受试物后0,5,15,30min,1,2,4,6,8,24h。血液样本采集后置于冰上，并于30分钟之内离心分离血浆(离心条件：5000转/分钟，10分钟，4℃)。分析前存放于–80℃。
(4)数据处理
数据采集及控制系统软件为Analyst1.5.1软件(Applied Biosystem)。图谱样品峰积分方式为自动积分；采用样品峰面积和内标峰面积的比值作为指标，和样品的浓度进行回归。回归方式：线性回归，权重系数为1/X2。药代动力学参数用WinNonlin Professional v6.3(Pharsight,USA)用非房室模型分析处理。Cmax为实测的最大血药浓度，血药浓度-时间曲线下面积AUC(0→t)由梯形法计算得到，Tmax为给药后血药浓度达峰时间。实验数据用“均数±标准差”(Mean±ICR,n≥3)或“均数”(Mean,n＝2) 表示。
(5)实验结果
化合物(-)-I-10的药代动力学结果如下表所示。由此可见，该化合物在C57雄性小鼠中具有良好的药代动力学性质。具体见表5。
表5
Figure PCTCN2022075094-appb-000109
备注：“--”表示不适用。
2.化合物(-)-I-10经灌胃、腹腔注射和静脉注射单次给予C57雄性小鼠的脑透过率测试
采用与药代动力学实验一致的方法，分别在0.5和2.0小时每只动物通过眼眶取0.030mL血液，EDTA-K2抗凝，血液样本采集后置于冰上，并于30分钟之内离心分离血浆(离心条件：5000转/分钟，10分钟，4℃)，分析前存放于–80℃。动物放血安乐死后取脑组织样品，用50％甲醇按照体重1：3匀浆(m/v＝1:3)，匀浆液分析前存放于–80℃。以LC/MS/MS方法分析血浆和脑组织中的药物浓度并进行比较。化合物(-)-I-10在0.5和2.0小时血浆和脑组织药物浓度及比值如表6所示。
表6
Figure PCTCN2022075094-appb-000110
测试例4：化合物对于精神分裂症样动物行为学模型的药效测试
1.空场运动能力测试
实验方法：实验动物为C57B6雄鼠，每组n＝8。此模型以C57B6小鼠为实验动物，通过急性注射NMDA拮抗剂MK801，诱导小鼠在空场环境中产生运动机能亢进的行为表征建模，用以检测不同化合物对MK801诱导的运动机能亢进表型的抑制效果。所有小鼠行为实验在小鼠的光照期进行，实验通过摄像头全程记录并通过行为学跟踪软件进行自动跟踪及进行数据统计。化合物通过腹腔注射给药，注射完成后，小鼠立刻进入空场并开始记录运动轨迹，30分钟后，小鼠通过腹腔注射接受0.2mg/kg的MK801，并在给药后立刻回到空场继续记录120分钟的运动轨迹。小鼠的累计移动距离按照每五分钟为一个数据采样点进行统计。数据统计使用Student-t-test进行，p<0.05为*，p<0.01为**，p<0.001为***，p<0.0001为****。不同剂量(-)-I-10与MK801(0.2mg/kg)联合作用下小鼠0-45分钟内的总移动距离见表7。
空场运动能力检测结果表明，化合物(-)-I-10在0.4/0.1/0.025mg/kg下能够显著抑制MK801所诱导的小鼠运动能力提升。
表7
Figure PCTCN2022075094-appb-000111
2.动物“抑郁样”行为测试
实验动物为C57B6雄鼠，每组n＝8。首先通过对C57B6小鼠进行5小时束缚，诱导小鼠产生抑郁相关的行为表征，进而通过悬尾以及强制游泳实验检测化合物对其“抑郁样”行为的影响。具体实验流程如下，首先使用尾静脉注射用小鼠固定器对小鼠进行束缚，束缚过程中在确保对小鼠造成最小疼痛的条件下，限制小鼠的一切行为能力。束缚开始前及结束后小鼠通过腹腔注射分别给药一次。束缚结束后小鼠回到饲养笼内恢复30分钟。30分钟后，不同组的小鼠分别进行悬尾或强制游泳对其“抑郁样”行为进行检测。
悬尾实验：小鼠尾尖通过胶布固定在铁架台的悬杆上，小鼠保持悬挂姿势6分钟。前2分钟为适应期，不进行数据采集，后4分钟内对小鼠的间断性不动行为进行时间记录。此不动状态的时间长度用以衡量小鼠的行为绝望成度。数据统计使用Student-t-test进行，p<0.05为*，p<0.01为**，p<0.001为***，p<0.0001为****。
强制游泳实验：小鼠放置于一个盛满水的5L玻璃烧杯内，水面高度为15cm,小鼠需要在烧杯中持续游泳6分钟。前两分钟为适应期，不进行数据采集。后四分钟内对小鼠的间断性不动行为进行时间记录，小鼠的不动行为定义为：小鼠被动漂浮在水面上不进行移动，并且仅存在维持漂浮所需的微 小局部运动。此不动状态的时间长度用以衡量小鼠的行为绝望成度。数据统计使用Student-t-test进行，p<0.05为*，p<0.01为**，p<0.001为***，p<0.0001为****。拘束与非拘束小鼠悬尾巴实验及强制游泳实验统计数据的结果如表8所示。
“抑郁样”行为检测结果表明，化合物(-)-I-10在0.4mg/kg和0.1mg/kg下能够显著抑制束缚所诱导“抑郁样”行为的产生。
表8
Figure PCTCN2022075094-appb-000112
3.新旧物体认知
实验动物为C57B6雄鼠，每组n＝8。首先连续七天，每天两次对小鼠进行0.3mg/kg的MK801腹腔注射进行认知障碍的造模，对照小鼠腹腔注射含有等量DMSO的生理盐水。随后小鼠在饲养笼内进行七天的回复。回复期满后，对小鼠进行新旧物体识别实验用以检测化合物对小鼠认知能力的影响。
新旧物体认知实验：实验在微光环境下进行，在实验开始前小鼠提前放置在实验场地内，在微光环境下进行一小时环境适应。环境适应结束后，小鼠通过腹腔注射进行给药。给药后30分钟，小鼠被放入一个预先放置好两个相同物体的空场内(空场直径40厘米)。小鼠在空场内进行10分钟的自由探索，随后从空场移除回到饲养笼内。经过一小时的间隔后，小鼠重新回到空场内，在空场内的相同位置上，预先放置了一个旧物体以及一个新物体。小鼠在空场内再次进行10分钟的自由探索。小鼠对于新旧物体的识别时间被分别记录并计算识别指标。识别指标的计算方法为，(新物体探索时间-旧物体探索时间)/(新物体探索时间+旧物体探索时间)。小鼠对物体的探索被定义为，面朝物体的嗅闻，攀爬，以及直接接触。数据统计使用Student-t-test进行，p<0.05为*，p<0.01为**，p<0.001为***，p<0.0001为****。新旧物体识别指标统计数据结果如表9所示。
新旧物体识别结果表明，化合物(-)-I-10在0.1mg/kg和0.025mg/kg下能够显著改善MK801所诱导的小鼠认知能力障碍。
表9
Figure PCTCN2022075094-appb-000113
Figure PCTCN2022075094-appb-000114
4.Morris水迷宫
实验动物为C57B6雄鼠，每组n＝8。首先连续十天，每天两次对小鼠进行0.2mg/kg的MK801腹腔注射进行认知障碍的造模，对照小鼠腹腔注射含有等量DMSO的生理盐水，随后对小鼠进行Morris水迷宫实验。
实验设置：实验在一个直径为130厘米的蓝色圆形蓄水池中进行。水池中注满约30厘米深的纯净水。水池被十字分割为4块扇形区域，逃生平台(直径6厘米)处于其中一个扇形区域中央，并隐藏于水面下0.5cm。小鼠入水位置固定在另外三个扇形区域的边缘。入水点位置与平台直线距离基本保持一致。
获得性训练：实验开始前30分钟，小鼠通过腹腔注射给药。实验开始后，将小鼠头朝水池壁放入水中，放置位置随机取东西南三个起始位置之一，水下隐藏平台位于北方象限。记录小鼠找到水下平台时间，如果1分钟内未找到平台，则引导小鼠至平台，让小鼠在平台上停留30秒。随后从另一起点开始重复以上步骤2次。每只动物每天训练三次，连续训练5天。
探查训练：最后一次获得性训练结束后的第二天，将平台撤除，开始60秒的探查训练。将动物由原先平台象限的对侧放入水中。记录动物穿越原平台位置的次数，以此作为空间记忆的检测指标。数据统计使用Student-t-test进行，p<0.05为*，p<0.01为**，p<0.001为***，p<0.0001为****。水迷宫获得性训练，每日平台探索时长结果如表10所示。
Morris水迷宫结果表明，化合物(-)-I-10在0.1mg/kg下能够显著改善MK801所诱导的小鼠空间认知能力障碍；化合物(-)-I-10在0.1mg/kg和0.025mg/kg下能够显著改善MK801所诱导的小鼠记忆能力障碍。
表10
Figure PCTCN2022075094-appb-000115
Figure PCTCN2022075094-appb-000116
5.僵直行为测试
实验方法：实验动物为C57B6雄鼠，每组n＝8。首先对小鼠注射不同的化合物，一定时间后(30分钟或60分钟)，通过将小鼠的前肢放置在一根位于高处的玻璃悬杆上(离地约5厘米)，让小鼠处于一种直立的非自然状态。随后检测小鼠维持这一状态不动的时间，以此时间长短来检测药物对小鼠产生的僵直效果。不同药物注射30及60分钟后，小鼠僵直行为检测结果如表11所示。
僵直行为测试表明，化合物(-)-I-10在10mg/kg下对于小鼠无僵直诱导效应。
表11
Figure PCTCN2022075094-appb-000117

Claims (11)

  1. 一种如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物：
    Figure PCTCN2022075094-appb-100001
    其中，L为C 1-10亚烷基、C 2-10亚烯基、C 2-10亚炔基或-C 1-6亚烷基-C 3-6亚环烷基-；
    M为-O-、-NH-、-CH 2-、-(CH-OH)-或-C(＝O)-；
    Q为C 6-18芳基、被1个或多个Q 1-1取代的C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；所述的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；所述的被1个或多个Q 1-2取代的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；
    Q 1-1独立地为卤素或C 1-4烷基；
    Q 1-2独立地为C 1-4烷基、氧代或羟基；
    R 1和R 2独立地为-NR 1-1R 1-2、3-6元杂环烷基、C 6-18芳基、被1个或多个R 1-3取代的C 6-18芳基、5-10元杂芳基或被1个或多个R 1-4取代的5-10元杂芳基；所述的3-6元杂环烷基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；所述的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；所述的被1个或多个R 1-4取代的5-10元杂芳基中的杂原子为N、S或O中的一种或多种，个数为1个、2个或3个；
    R 1-1、R 1-2、R 1-3和R 1-4独立地为C 1-4烷基；
    R为氢或C 1-4烷基。
  2. 如权利要求1所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，其特征在于，所述的如式I所示的化合物为如下任一情形所述：
    情形1：
    所述的如式I所示的化合物为如式Ia、Ib或Ic所示的化合物：
    Figure PCTCN2022075094-appb-100002
    式Ic中，
    Figure PCTCN2022075094-appb-100003
    表示双键或单键；Y为氢、羟基或氧；
    情形2：
    所述的如式I所示的化合物为如式Id和/或Ie所示的化合物，优选如式Id所示的化合物；
    Figure PCTCN2022075094-appb-100004
    情形3：
    当所述的如式I所示的化合物仅在
    Figure PCTCN2022075094-appb-100005
    中具有一个手性中心时，
    Figure PCTCN2022075094-appb-100006
    为
    Figure PCTCN2022075094-appb-100007
    和/或
    Figure PCTCN2022075094-appb-100008
    优选
    Figure PCTCN2022075094-appb-100009
  3. 如权利要求1所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，其特征在于，所述的如式I所示的化合物为如下任一方案：
    方案1：
    L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
    M为-O-、-NH-或-CH 2-；
    Q为C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；
    方案2：
    L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
    M为-O-、-NH-或-CH 2-；
    Q为C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；
    当M为-O-时，Q 1-2为C 1-4烷基或羟基；
    当所述的5-10元杂芳基中的杂原子为O时，所述的5-10元杂芳基中杂原子的个数为1个；
    方案3：
    L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
    M为-O-、-NH-或-CH 2-；
    Q为C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基、-C(＝O)R 1或-S(＝O) 2R 2；
    当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基-中的C 1-6亚烷基为亚乙基；
    方案4：
    L为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基-；
    M为-O-或-NH-；
    Q为-C(＝O)R 1或被1个或多个Q 1-2取代的5-10元杂芳基；
    R 1为-NR 1-1R 1-2；
    方案5：
    所述的如式I所示的分子结构为如式Ia所示：
    Figure PCTCN2022075094-appb-100010
    L为C 1-10亚烷基或C 2-10亚烯基；
    Q为被1个或多个Q 1-1取代的C 6-18芳基、5-10元杂芳基、被1个或多个Q 1-2取代的5-10元杂芳基；
    Q 1-1为卤素；
    方案6：
    所述的如式I所示的分子结构为如式Ib所示：
    Figure PCTCN2022075094-appb-100011
    L为-C 1-6亚烷基-C 3-6亚环烷基-；
    Q为-C(＝O)R 1或-S(＝O) 2R 2；
    R 1和R 2独立地为-NR 1-1R 1-2、3-6元杂环烷基、C 6-18芳基或5-10元杂芳基；
    方案7：
    所述的如式I所示的分子结构为如式Ic所示：
    Figure PCTCN2022075094-appb-100012
    Figure PCTCN2022075094-appb-100013
    表示双键或单键；
    Y为氢、羟基或氧；
    L为C 1-10亚烷基；
    Q为被1个或多个Q 1-1取代的C 6-18芳基、或、被1个或多个Q 1-2取代的5-10元杂芳基；
    Q 1-1为卤素；
    Q 1-2独立地为C 1-4烷基或氧代；
    方案8：
    L为C 1-10亚烷基、C 2-10亚烯基或-C 1-6亚烷基-C 3-6亚环烷基-；
    当M为-(CH-OH)-或-C(＝O)-时，R为氢；
    方案9：
    L为C 1-10亚烷基；
    M为-O-；
    Q为被1个或多个Q 1-2取代的5-10元杂芳；
    方案10：
    L为-C 1-6亚烷基-C 3-6亚环烷基-；
    M为-NH-；
    Q为-C(＝O)R 1；
    R 1为-NR 1-1R 1-2；
    方案11：
    所述的如式I所示的分子结构为如式Ia所示：
    Figure PCTCN2022075094-appb-100014
    L为C 1-10亚烷基或C 2-10亚烯基；
    Q为5-10元杂芳基、或、被1个或多个Q 1-2取代的5-10元杂芳基；
    方案12：
    所述的如式I所示的分子结构为如式Ic-1所示：
    Figure PCTCN2022075094-appb-100015
    L为C 1-10亚烷基；
    Q为被1个或多个Q 1-1取代的C 6-18芳基；
    Q 1-1为卤素；
    R为氢；
    方案13：
    所述的如式I所示的分子结构为如式Ic-2所示：
    Figure PCTCN2022075094-appb-100016
    L为C 1-10亚烷基；
    Q为被1个或多个Q 1-1取代的C 6-18芳基；
    Q 1-1为卤素；
    R为氢；
    方案14：
    所述的如式I所示的分子结构为如式Ic-3所示：
    Figure PCTCN2022075094-appb-100017
    L为C 1-10亚烷基；
    Q为被1个或多个Q 1-2取代的5-10元杂芳基；
    Q 1-1为C 1-4烷基或氧代；
    R为氢。
  4. 如权利要求1所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，其特征在于，当L为C 1-10亚烷基时，所述的C 1-10亚烷基为亚甲基、亚乙基、亚正丙基、亚异丙基、亚正丁基、亚异丁基或亚叔丁基，优选
    Figure PCTCN2022075094-appb-100018
    更优选为
    Figure PCTCN2022075094-appb-100019
    和/或，当L为C 2-10亚烯基时，所述的C 2-10亚烯基为C 2-4亚烯基，优选为
    Figure PCTCN2022075094-appb-100020
    和/或，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的C 1-6亚烷基与N相连接，所述的C 3-6亚环烷基与Q相连接；
    和/或，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基中C 1-6亚烷基为亚甲基、亚乙基、亚正丙基、亚异丙基、亚正丁基、亚异丁基或亚叔丁基，优选亚甲基或
    Figure PCTCN2022075094-appb-100021
    更优选为
    Figure PCTCN2022075094-appb-100022
    和/或，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基中C 3-6亚环烷基为亚环丙基、亚环丁基、亚环戊基或亚环己基，优选为
    Figure PCTCN2022075094-appb-100023
    和/或，当Q为C 6-18芳基时，所述的C 6-18芳基为苯基、萘基、蒽基或菲基，优选为苯基；
    和/或，当Q为Q 1-1取代的C 6-18芳基时，所述的C 6-18芳基为苯基、萘基、蒽基或菲基，优选为苯基；
    和/或，当Q为Q 1-1取代的C 6-18芳基时，所述的Q 1-1为1个或2个；
    和/或，当Q 1-1为卤素时，所述的卤素为F、Cl、Br或I，优选为F；
    和/或，当Q为5-10元杂芳基时，所述的5-10元杂芳基为9或10元杂芳基，杂原子个数为1个或2个，进一步优选为
    Figure PCTCN2022075094-appb-100024
    和/或，当Q为被1个或多个Q 1-2取代的5-10元杂芳基时，所述的5-10元杂芳基为9或10元杂芳基，杂原子为N和/或O，个数为1个或2个，优选为四氢喹啉基、喹啉基、苯并噁唑基、苯并异噁唑基或四氢吡啶并嘧啶基；
    和/或，当Q为Q 1-2取代的C 6-18芳基时，所述的Q 1-2为1个或2个；
    和/或，当Q 1-2为C 1-4烷基时，所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基，优选为甲基；
    和/或，当R 1和R 2独立地为3-6元杂环烷基时，所述的3-6元杂环烷基为哌啶基或吡咯烷基，优选为吡咯烷基；
    和/或，当R 1为3-6元杂环烷基时，所述的3-6元杂环烷基通过杂原子与羰基相连接；
    和/或，当R 1和R 2独立地为C 6-18芳基时，所述的C 6-18芳基为苯基、萘基、蒽基或菲基，优选为苯基；
    和/或，当R 1和R 2独立地为被1个或多个R 1-3取代的C 6-18芳基时，所述的C 6-18芳基为苯基、萘基、蒽基或菲基，优选为苯基；
    和/或，当R 1和R 2独立地为5-10元杂芳基时，所述的5-10元杂芳基为9或10元杂芳基，杂原子为N，个数为1个或2个，优选为吲哚基；
    和/或，当R 1-1、R 1-2、R 1-3和R 1-4独立地为C 1-4烷基时，所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基，优选为甲基；
    和/或，当R为C 1-4烷基时，所述的C 1-4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基，优选为甲基。
  5. 如权利要求4所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，其特征在于，当L为-C 1-6亚烷基-C 3-6亚环烷基-时，所述的-C 1-6亚烷基-C 3-6亚环烷基-为
    Figure PCTCN2022075094-appb-100025
    优选
    Figure PCTCN2022075094-appb-100026
    其中a端与Q相连接，b端与N相连接；
    和/或，当Q为Q 1-1取代的C 6-18芳基时，所述的Q 1-1取代的C 6-18芳基为
    Figure PCTCN2022075094-appb-100027
    和/或，当Q为被1个或多个Q 1-2取代的5-10元杂芳基时，所述的被1个或多个Q 1-2取代的5-10元杂芳基为
    Figure PCTCN2022075094-appb-100028
    Figure PCTCN2022075094-appb-100029
    和/或，当R 1为3-6元杂环烷基时，所述的3-6元杂环烷基为
    Figure PCTCN2022075094-appb-100030
    和/或，
    Figure PCTCN2022075094-appb-100031
    为
    Figure PCTCN2022075094-appb-100032
    Figure PCTCN2022075094-appb-100033
  6. 如权利要求1所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，其特征在于，L为C 1-10亚烷基、C 2-10亚烯基或-C 1-6亚烷基-C 3-6亚环烷基，优选为C 1-10亚烷基或-C 1-6亚烷基-C 3-6亚环烷基；
    和/或，M为-O-、-NH-或-CH 2-；
    和/或，Q 1-1为卤素；
    和/或，R 1为-NR 1-1R 1-2、3-6元杂环烷基、C 6-18芳基或5-10元杂芳基，优选为-NR 1-1R 1-2、3-6元杂环烷基或C 6-18芳基；
    和/或，R为氢。
  7. 如权利要求1所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，其特征在于，所述的如式I所示的化合物为如下任一化合物：
    Figure PCTCN2022075094-appb-100034
    Figure PCTCN2022075094-appb-100035
    优选
    Figure PCTCN2022075094-appb-100036
    “旋光值为+50.33°和/或在如下手性制备条件下保留时间为5.805min的
    Figure PCTCN2022075094-appb-100037
    ”或“旋光值为-45.00°和/或在下述手性制备条件下保留时间为7.60min的
    Figure PCTCN2022075094-appb-100038
    ”；
    所述的手性制备条件：色谱柱：手性柱CHIRALCEL OD，柱体积：5.0cmx 25cm，10μm填料；流动相：MeOH/二乙胺＝100/0.1；流速：30mL/min；波长：UV 214nm；温度：38℃。
  8. 一种如式pNs-(+)-I-10所示的晶体，其特征在于，其晶系属于三斜晶系，P1空间群，晶胞参数为
    Figure PCTCN2022075094-appb-100039
    α＝90.15°，β＝99.368°，γ＝90.25°；
    Figure PCTCN2022075094-appb-100040
  9. 一种药物组合物，其包括如权利要求1-7中的任一项所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物或如权利要求8所述的如式pNs-(+)-I-10所示的晶体、和药用辅料。
  10. 一种物质A的应用；所述的应用为用于制备多巴胺D2受体激动剂、用于治疗和/或预防与多巴胺D2受体相关疾病的药物或用于治疗和/或预防疾病M的药物中的应用；
    所述的疾病M为神经退行性疾病、精神异常类疾病和与精神异常类相关的代谢性疾病中的一种或多种；
    所述的物质A为如权利要求1-7中的任一项所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物、如权利要求8所述的如式pNs-(+)-I-10所示的晶体或如权利要求9所述的药物组合物。
  11. 一种预防或治疗与多巴胺D2受体相关疾病或疾病M的方法，其包括给予受试者治疗有效量的物质A；
    所述的疾病M为神经退行性疾病、精神异常类疾病和与精神异常类相关的代谢性疾病中的一种或多种；
    所述的物质A为如权利要求1-7中的任一项所述的如式I所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物、如权利要求8所述的如式pNs-(+)-I-10所示的晶体或如权利要求9所述的药物组合物；
    所述的方法中，所述的疾病M优选为帕金森氏症、阿尔茨海默症或痴呆症、精神分裂症、双向情感障碍、抑郁症、多动症、不安腿综合症、亨廷顿舞蹈症、男性勃起障碍、泌乳素瘤或毒品成瘾。
PCT/CN2022/075094 2021-02-01 2022-01-29 氮杂麦角林类衍生物及其制备方法和应用 WO2022161493A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023546362A JP2024504499A (ja) 2021-02-01 2022-01-29 アザ－エルゴリン系誘導体及びその製造方法と使用
US18/274,889 US20240124456A1 (en) 2021-02-01 2022-01-29 Aza-ergoline derivative and preparation method therefor and application thereof
EP22745364.4A EP4286384A1 (en) 2021-02-01 2022-01-29 Aza-ergoline derivative and preparation method therefor and application thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110138249 2021-02-01
CN202110138249.9 2021-02-01
CN202111153079.8 2021-09-29
CN202111153079.8A CN114835709B (zh) 2021-02-01 2021-09-29 氮杂麦角林类衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2022161493A1 true WO2022161493A1 (zh) 2022-08-04

Family

ID=82562568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/075094 WO2022161493A1 (zh) 2021-02-01 2022-01-29 氮杂麦角林类衍生物及其制备方法和应用

Country Status (5)

Country Link
US (1) US20240124456A1 (zh)
EP (1) EP4286384A1 (zh)
JP (1) JP2024504499A (zh)
CN (1) CN114835709B (zh)
WO (1) WO2022161493A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088838A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands
WO2011088836A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088838A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands
WO2011088836A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLAIR, DRUGS, vol. 80, no. 4, 2020, pages 417 - 423
FANTAN ET AL., NAT COMM, vol. 11, 2020, pages 1074
FRANKELSCHWARTZ, THE ADV PSYCHOPHARMACOL, vol. 7, no. 1, 2017, pages 29 - 41
KROGSGAARD-LARSEN ET AL., J. MED. CHEM, vol. 57, 2014, pages 5823 - 5828
KROGSGAARD-LARSEN ET AL., J. MED. CHEM., vol. 57, 2014, pages 5823 - 5828
KROGSGAARD-LARSEN NIELS, JENSEN ANDERS A., SCHRØDER TENNA J., CHRISTOFFERSEN CLAUS. T., KEHLER JAN: "Novel Aza-analogous Ergoline Derived Scaffolds as Potent Serotonin 5-HT 6 and Dopamine D 2 Receptor Ligands.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 13, 10 July 2014 (2014-07-10), US , pages 5823 - 5828, XP055954880, ISSN: 0022-2623, DOI: 10.1021/jm5003759 *
KROGSGAARD-LARSEN, N. ; BEGTRUP, M. ; FRYDENVANG, K. ; KEHLER, J.: "Syntheses of aza-analogous iso-ergoline scaffolds using carbene mediated C-H insertion", TETRAHEDRON, vol. 66, no. 47, 20 November 2010 (2010-11-20), AMSTERDAM, NL , pages 9297 - 9303, XP027443744, ISSN: 0040-4020 *
SAHLITARAZI, EXPERT OPIN DRUG DISCOV, vol. 13, no. 1, 2018, pages 103 - 110

Also Published As

Publication number Publication date
CN114835709A (zh) 2022-08-02
US20240124456A1 (en) 2024-04-18
CN114835709B (zh) 2023-10-20
JP2024504499A (ja) 2024-01-31
EP4286384A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
CN111138448B (zh) 抑制rip1激酶的杂环酰胺及其用途
JP6059723B2 (ja) ４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用
WO2021068898A1 (zh) 新颖的kras g12c蛋白抑制剂及其制备方法和用途
TW201718490A (zh) Lsd1抑制劑之鹽
CN106794364B (zh) 取代的4-苯基哌啶及其制备和用途
TW200418829A (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EA016234B1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
TWI424998B (zh) 作為腺苷A3受體配體的三唑并[1,5-a]喹啉類
AU2021208915B2 (en) Novel pyrazole derivative
TWI648276B (zh) 雜環化合物
JP2012520246A (ja) Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
CN110291073A (zh) 乙酰肝素酶抑制剂及其用途
WO2024148788A1 (zh) 并环哌啶类化合物及其制备方法和用途
CN108137477A (zh) 治疗化合物及其使用方法
EP1923387A1 (en) Acylguanidine derivative or salt thereof
AU2004237130A1 (en) Positive modulators of nicotinic acetylcholine receptors
WO2023280288A1 (zh) 一种吡咯磺酰类衍生物、及其制备方法与应用
KR20020027647A (ko) Ｄ4 길항제로서 유용한, 티에노이속사졸릴- 및티에닐피라졸릴-페녹시 치환된 프로필 유도체
WO2022166983A1 (zh) 杂芳基并哌啶类衍生物及其药物组合物和应用
CN115916766A (zh) 新型吡唑衍生物
WO2022161493A1 (zh) 氮杂麦角林类衍生物及其制备方法和应用
WO2019129025A1 (zh) 四氢吡咯类化合物、其制备方法、药物组合物及用途
TW201741316A (zh) 四氫異喹啉衍生物
JP2017503799A (ja) カッパオピオイドアゴニストとしての複素二環式化合物
WO2023036177A1 (zh) 噻吩并环化合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22745364

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 18274889

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2023546362

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12023552102

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2022745364

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022745364

Country of ref document: EP

Effective date: 20230901

WWE Wipo information: entry into national phase

Ref document number: 11202305788W

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2022745364

Country of ref document: EP

Effective date: 20230901